Upload
strata-media-group
View
217
Download
1
Tags:
Embed Size (px)
DESCRIPTION
The final book for Ovarian Club II congress
Citation preview
The fertilization process of the oocyte and embryo development in relation to various clinical conditions
Dorint Hotel Don Giovanni PraGUe Prague, CzeCh rePubliC • November 8-11, 2012
PROGRAM
www.comtecmed.com/OC/2012 • [email protected]
MENOPUR Multidose is now available,offering a more convenient treatment option
compared to MENOPUR 75 IU3
MENOPUR Multidose is now available,offering a more convenient treatment option
compared to MENOPUR 75 IU3
Ferring International Center SAChemin de la Vergognausaz 50CH 1162 St-PrexSwitzerlandwww.ferring.com
More live births with MENOPUR®
vs. rFSH following IVF1,2
A fact you can hold on to
More live births with MENOPUR®
vs. rFSH following IVF1,2
A fact you can hold on to
OC II cover-RUN.indd 1 22/10/12 12:21:19
Ovarian Club IIMeeting
Friday, November 9th 201213.45 –14.15 h
Prague, Czech RepublicNovember 8 –11, 2012
Company Presentation on„New Horizons: The voice ofthe industry“
Julian Platon, MD PhD
The fertilization process of the oocyte and embryo development in relation to various clinical conditions
Dupha_Anz_Ovarian_Club_RZ 11.10.2012 10:55 Uhr Seite 1
Shortened summary of MENOPUR 1200 IU and 600 IU characteristics
Name of the product: MENOPUR 1200 IU. Powder for solution
for injection + solvent. MENOPUR 600 IU. Powder for solution
for injection + solvent. Composition: Menopur 1200 IU: Highly
purified HMG equal to 1200 IU FSH and 1200 IU LH in one vial.
Menopur 600 IU: Highly purified HMG equal to 600 IU FSH
and 600 IU LH in one vial. Indications: Treatment for infertility
in women and men (in women with anovulation who fail to
respond to treatment with clomiphene citrate; controlled ovarian
hyperstimulation during assisted reproduction; in men with
hypo/ normogonadotrophic hypogonadism). For details see SPC.
Contraindications: Hormone-dependent cancers. Gynaecological
haemorrhage of unknown aetiology, premature menopause,
enlarged ovaries and cysts (polycystic ovarian syndrome), states
incompatible with pregnancy. Pregnancy and lactation. Excessive
sensitivity to any of the medicinal product ingredients. For
details see SPC. Posology: individual, i.m. or s.c. administration.
For details see SPC. Special warnings (and special precautions
for use). Ovarian response to treatment ought to be monitored
owing to threatened ovarian enlargement or development of
OHSS. Potentially increased risk of thromboembolic disease
developing in women at high risk. Pregnancy and lactation: see
section Contraindications. Undesirable effects: Headache and
abdominal pain, nausea, vomiting, enlargement of abdominal
cavity, pelvic pain, OHSS, thromboembolic disease, reactions
at the site of injection, hypersensitivity. Overdose: Threatened
development of ovarian hyperstimulation. Interaction: No
interaction studies have been undertaken. Special precautions
for storage: Store in refrigerator (2°C - 8°C), after preparation
the solution can be stored at up to 25°C for a maximum period
of 28 days. Marketing authorisation holder: Ferring Léc iva, Inc.
Jesenice u Prahy, Czech Republic. Marketing authorisation
number: Menopur 1200 IU: 56/961/10-C, Menopur 600 IU:
56/960/10-C. Date of revision of the text: 01/06/2011. Available
solely against medical prescription. No coverage from public
health insurance funds. Prior to prescription, please seek full
information on the medicinal product at the following address:
FERRING Pharmaceuticals CZ s.r.o, K Rybníku 475, 252 42
Jesenice u Prahy. Telephone: +420 241 041 111
Adverse events should be reported.
Reporting forms and information can be found at www.yellowcard.gov.uk.
Adverse events should also be reported to Ferring Pharmaceuticals Ltd.
OC II cover-RUN.indd 2 22/10/12 12:21:39
The fertilization process of the oocyte, embryo development and implantation in relation to various clinical conditionsDorint Hotel Don Giovanni Prague • Prague, Czech Republic • November 8-11, 2012
23
The fertilization process of the oocyte and embryo development in relation to various clinical conditions
Dorint Hotel Don Giovanni PraGUe Prague, CzeCh rePubliC • November 8-11, 2012
PROGRAM
www.comtecmed.com/OC/2012 • [email protected]
Ovarian Club IIMeeting
Friday, November 9th 201213.45 –14.15 h
Prague, Czech RepublicNovember 8 –11, 2012
Company Presentation on„New Horizons: The voice ofthe industry“
Julian Platon, MD PhD
The fertilization process of the oocyte and embryo development in relation to various clinical conditions
Dupha_Anz_Ovarian_Club_RZ 11.10.2012 10:55 Uhr Seite 1
01-12-OC II- part 1.indd 3 22/10/12 12:02:04
Fostimon®
Highly purified hFSH
Listen to the oocyte
Evidence of life
Adv Fostimon A4 2011_rev10_3_11.indd 1 10.03.11 08.18
01-12-OC II- part 1.indd 4 22/10/12 12:02:08
The fertilization process of the oocyte, embryo development and implantation in relation to various clinical conditionsDorint Hotel Don Giovanni Prague • Prague, Czech Republic • November 8-11, 2012
3
Fostimon®
Highly purified hFSH
Listen to the oocyte
Evidence of life
Adv Fostimon A4 2011_rev10_3_11.indd 1 10.03.11 08.18
TiMeTAble
THuRsDay, NovembeR 8, 2012
FRiDay, NovembeR 9, 2012
14:30-16:30 SeSSion 1: Harvesting and Harnessing Human ovarian Stem Cells Supported by an unrestricted grant by IBSA
16:30-17:00 Coffee Break/Poster Viewing
17:00-19:00 SeSSion 2: The Mystery of Fertility Preservation
19:00 ovarian Club Meet & Greet
08:30-10:30 SeSSion 3: Recruitment, follicular development and oocyte competence Supported by an unrestricted grant by IBSA
10:30-11:00 Coffee Break/ Poster Viewing
11:00-13:00 SeSSion 4: The environmental influence of oocytes and embryos
13:00-13:45 Lunch Break
13:45-14:15 new HoRizonS: THe VoiCe oF THe induSTRy Company symposium sponsored by Abbott
14:15-15:45 SeSSion 5: oocytes and embryos: Clinical Relevance
15:45-16:15 Coffee Break/ Poster Viewing
16:15-18:15 SeSSion 6: Biomarkers: Clinical Relevance Endorsed by IVI
18:15 ovarian Club Meet & Greet
saTuRDay, NovembeR 10, 2012
08:30-10:30 SeSSion 7: Clinical implication of iCSi failure Supported by an unrestricted grant by IBSA
10:30-11:00 Coffee Break/ Poster Viewing
11:00-13:00 SeSSion 8: Metabolic programming during the preconception period and implications for subsequent fetal, neo-natal and adult health
13:00-13:45 Lunch Break
13:45-14:15 new HoRizonS: THe VoiCe oF THe induSTRy Company symposium sponsored by Ferring
14:15-16:15 SeSSion 9: The Fertilization Process
16:15-16:45 Coffee Break/ Poster Viewing
16:45-18:45 SeSSion 10: Aging
suNDay, NovembeR 11, 2012
Travel day
01-12-OC II- part 1.indd 5 22/10/12 12:02:10
The fertilization process of the oocyte, embryo development and implantation in relation to various clinical conditionsDorint Hotel Don Giovanni Prague • Prague, Czech Republic • November 8-11, 2012
4
Table of ConTenTs
Welcome Note 5
Organizing Committee 6
Club Speakers 7
CME Accreditation 8
Sponsors 9
List of Sponsors 10
General Information 11
Scientific Program 13
Thursday, November 8, 2012 14
Friday, November 9, 2012 15
Saturday, November 10, 2012 17
Club Speakers’ Overviews 21
Posters 39
Index 49
01-12-OC II- part 1.indd 6 22/10/12 12:28:14
The fertilization process of the oocyte, embryo development and implantation in relation to various clinical conditionsDorint Hotel Don Giovanni Prague • Prague, Czech Republic • November 8-11, 2012
After the success of the 1st Meeting of the ovarian Club (Barcelona, Spain, november 3-6, 2011), we would like to welcome you to the ovarian Club ii: The fertilization process of the oocyte and embryo development in relation to various clinical conditions, Prague, Czech Republic, november 8-10, 2012.
The field of Reproductive Medicine is experiencing vast expansion in clinical trials and basic research as well as in emerging cutting-edge technology. new agents will be entering the clinical realm in the coming years.
The "ovarian Club" will function as a comprehensive forum where international experts share and present state-of-the–art management issues with the participants in order to outline the optimal treatment for patients.
Participants are provided the opportunity to discuss and brainstorm with well-known speakers and experts from all over the world.
The "ovarian Club" forum aims to help clinicians to reach reliable solutions that can be implemented in their daily practices.
The "ovarian Club" will allow researchers to present their new studies and findings in their fields of expertise creating an inter-active platform for discussions with the leading experts who will attend the Meeting.
we hope you will enjoy the scientific program and the beautiful city of Prague!
Sincerely yours,
The Organizing Committee
Dear Friends and Colleagues
P. bouchard, FranceP. Devroey, BelguimJ. eppig, USAb. Fauser, The NetherlandsR. Fleming, UKs. Hamamah, FranceK. Korach, USA
s. mashiach, IsraelJ. motlik, Czech RepublicG. schatten, USAZ. shoham, IsraelJ. smitz, Belgiume. Telfer, UKJ. Thompson, Australia
01-12-OC II- part 1.indd 7 22/10/12 12:02:14
The fertilization process of the oocyte, embryo development and implantation in relation to various clinical conditionsDorint Hotel Don Giovanni Prague • Prague, Czech Republic • November 8-11, 2012
6
ORGAnizinG COMMiTTee
Philippe bouchard France
Ken KorachUSA
Zeev shohamIsrael
Paul DevroeyBelgium
shlomo mashiachIsrael
Johan smitzBelgium
John eppigUSA
Jan motlikCzech Republic
evelyn TelferUK
bart FauserThe Netherlands
Richard FlemingUK
samir HamamahFrance
Gerald schattenUSA
Jeremy Thompson Australia
01-12-OC II- part 1.indd 8 22/10/12 12:02:20
The fertilization process of the oocyte, embryo development and implantation in relation to various clinical conditionsDorint Hotel Don Giovanni Prague • Prague, Czech Republic • November 8-11, 2012
7
David albertini, USAellen anckaert, Belgiumamir arav, Israelesther baart, The NetherlandsPiergiorgio Crosignani, ItalyRabindranath De La Fuente, USANava Dekel, IsraelDominique De Ziegler, Franceadrian ellenbogen, IsraelTom Fleming, UKshevach Friedler, IsraelNorbert Gleicher, USAsatish Gupta, Indiasamir Hamamah, FranceGeraldine Hartshorne, UKmary Herbert, UKJohn C. Herr, USAariel Hourvitz, IsraelPatricia Hunt, USAKenneth Korach, USAmaria Lalioti, USAshlomo mashiach, Israel marcos meseguer, Spain
Kelle H. moley, USAJan motlik, Czech RepublicNicole Noyes, USAJean-Pierre ozil, FrancePasquale Patrizio, USAPatrick Quinn, USACarmen Rubio, SpainDenny sakkas, USAGerald schatten, USAemre seli, USAaritro sen, USAZeev shoham, Israelsherman silber, USACarlos simón, SpainKevin sinclair, UKPeter svoboda, Czech Republicevelyn Telfer, UKJeremy Thompson, AustraliaJonathan Tilly, USAJonathan van blerkom, USADori Woods, USAGwo-Jang Wu, Taiwan
Club sPeAkeRs
01-12-OC II- part 1.indd 9 22/10/12 12:02:25
The fertilization process of the oocyte, embryo development and implantation in relation to various clinical conditionsDorint Hotel Don Giovanni Prague • Prague, Czech Republic • November 8-11, 2012
8
CMe ACCRediTATiOn
The ovarian Club ii: The fertilization process of the oocyte and embryo development in relation to various clinical conditions was granted 15 european CMe credits (eCMeC) by the european Accreditation Council for Continuing Medical education (eACCMe).
euRoPeaN aCCReDiTaTioNeuropean Accreditation is granted by the eACCMe in order to allow participants who attend the above-mentioned activity to validate their credits in their own country.
aCCReDiTaTioN sTaTemeNTAccreditation by the eACCMe confers the right to place the following statement in all communication materials including the registration website, the event program and the certificate of attendance. The following statements must be used without revision: The ovarian Club ii: The fertilization process of the oocyte and embryo development in relation to various clinical conditions' (or) 'ovarian Club ii: The fertilization process of the oocyte and embryo development in relation to various clinical conditions' is accredited by the european Accreditation Council for Continuing Medical education (eACCMe) to provide the following CMe activity for medical specialists. The eACCMe is an institution of the european union of Medical Specialists (ueMS), www.uems.net.
The 'ovarian Club ii: The fertilization process of the oocyte and embryo development in relation to various clinical conditions' is designated for a maximum of (or 'for up to') 15 hours of european external CMe credits. each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.
Through an agreement between the european union of Medical Specialists and the American Medical Association, physicians may convert eACCMe credits to an equivalent number of AMA PRA Category 1 Credits™. information on the process to convert eACCMe credit to AMA credit can
be found at www.ama-assn.org/go/internationalcme.
Live educational activities, occurring outside of Canada, recognized by the ueMS-eACCMe for eCMeC credits are deemed to be Accredited Group.
Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.
eaCCme CReDiTseach medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. The eACCMe credit system is based on 1 eCMeC per hour with a maximum of 3 eCMeCs for half a day and 6 eCMeCs for a full-day event.
01-12-OC II- part 1.indd 10 22/10/12 12:02:25
The fertilization process of the oocyte, embryo development and implantation in relation to various clinical conditionsDorint Hotel Don Giovanni Prague • Prague, Czech Republic • November 8-11, 2012
9
sPOnsORs
The Ovarian Club Meeting gratefully acknowledges the generous support of the Sponsors
Institut Biochimique SA
01-12-OC II- part 1.indd 11 22/10/12 12:02:26
The fertilization process of the oocyte, embryo development and implantation in relation to various clinical conditionsDorint Hotel Don Giovanni Prague • Prague, Czech Republic • November 8-11, 2012
10
ACknOwledGeMenTs
Institut Biochimique SA
Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 91,000 people and markets its products in more than 130 countries. Abbott's news releases and other information are available on the company's web site at www.abbott.com.
Ferring Pharmaceuticals is a research-driven biopharmaceutical company devoted to identifying, developing and marketing innovative products in the fields of reproductive health, urology, gastroenterology, endocrinology and osteoarthritis. The company’s research activities and products are connected by a common thread focused on the provision of tailored treatments that work on the body’s own terms to enable doctors to combat numerous diseases and medical conditions. The company has gained international recognition over the last 20 years for the creation of inventive medications that improve the quality of life of children and adults all around the world. To learn more about Ferring or our products please visit www.ferring.com.
iBSA is an international pharmaceutical company headquartered in Lugano, Switzerland, delivering different therapeutic solutions for follicular stimulation and luteal support.iBSA developed an entirely new purification process to obtain a full range of highly purified, human gonadotrophins: hFSH, hMG and hCG.This unique patented process was conceived to ensure at the same time both high purity and the respect of the structure–correlate activities of the gonadotrophins (natural glycosylation).iBSA’s whole in-house manufacturing ensures the same global quality system in company owned plants, from the first steps of raw materials to the final lyophilized products.other company's franchises include osteoarthritis, pain-management, dermatology and thyroid diseases.
abbott Products operations aGContact person: Julian V. PlatonHegenheimermattweg 1274123 AllschwilSwitzerlandTel: +41 61 487 0200Fax: +41 61 487 0299email: [email protected]
Ferring PharmaceuticalsFerring international Center S.ACh. de la Vergognausaz 50, 1162 Saint-Prex, SwitzerlandTel: +41 58 301 00 00Fax: +41 58 301 03 71www.ferring.com
ibsa institut biochimique saVia del Piano, P.o. Box 266, 6915 Pambio-noranco, Lugano, SwitzerlandTel: +41 58 360 10 00Fax: +41 58 360 16 47email: [email protected]
01-12-OC II- part 1.indd 12 22/10/12 12:02:27
The fertilization process of the oocyte, embryo development and implantation in relation to various clinical conditionsDorint Hotel Don Giovanni Prague • Prague, Czech Republic • November 8-11, 2012
11
GeneRAl infORMATiOn
meeTiNG veNuedorint Hotel don Giovanni Prague Vinohradská 157a13020 Prague, Czech Republic
LaNGuaGe english is the official language of the Meeting.
CLoTHiNGinformal for all occasions
ReGisTRaTioN aND HosPiTaLiTy DesK oPeNiNG HouRsThe registration desk will operate during the following hours:
Thursday, november 8, 2012 12:00-18:30
Friday, november 9, 2011 07:30-18:00
Saturday, november 10, 2012 08:00-19:00
meeTiNG KiT aND NameTaGnametags are included in your personal Meeting kit. Please wear your nametag during all sessions and social events.Key colors for nametags:
PRevieW RoomClub Speakers are required to visit the preview room. Please come to the Speakers preview room 24 hours before (or at least three hours prior to the lecture) with your slide presentations to be ready to be uploaded for your session.
PosTeR DisPLaysPosters should be mounted for Group A: From Thursday, november 8, 2012 at 17:00 and are to be dismantled by the Poster Presenter no later than 18:15 on Friday, november 9, 2012.Posters should be mounted for Group B: From Friday, november 9, 2012 at 18:15 and are to be dismantled by the Poster Presenter no later than 18:45 on Saturday, november 10, 2012.Poster presenters should plan to be alongside their posters during the coffee breaks.The organizing Committee is not responsible for posters that are not removed on time.
Dark blue: Club Members Orange: Club Speakers
Prague, CzeCh rePubliC • November 8-11, 2012
The fertilization process of the oocyte and embryo development in relation to various clinical conditions
Prague, CzeCh rePubliC • November 8-11, 2012
The fertilization process of the oocyte and embryo development in relation to various clinical conditions
01-12-OC II- part 1.indd 13 22/10/12 12:02:33
The fertilization process of the oocyte, embryo development and implantation in relation to various clinical conditionsDorint Hotel Don Giovanni Prague • Prague, Czech Republic • November 8-11, 2012
12
GeneRAl infORMATiOn
Cme aCCReDiTaTioNPlease note that you have your CMe Accreditation Form in your kit. in order to receive your accreditation points, please submit the completed form to the registration desk before the end of the Meeting. your certificate will be sent to you directly.
LuNCHesBuffet lunch will be served for Club Members between 13:00-13:45 on both Friday, november 9, 2012 & Saturday, november 10, 2012.
CoFFee bReaKsCoffee/tea will be served in the Poster Board area during the coffee breaks between sessions as specified on the time table.
ovaRiaN CLub meeT & GReeTThe ovarian Club Meet and Greet gives all oC ii participants an opportunity to mingle and interact with one another.drink and snacks will be served. Come and join us.
LisT oF CLub membeRsA list of pre-registered club members is displayed on the notice board. Please correct or add your name and address wherever necessary.
CeRTiFiCaTioN oF aTTeNDaNCeyour Certificate of Attendance is included in your personal Meeting kit.
WiFiwifi internet will be available at the dorint Hotel Giovanni free of charge.
saFeTy aND seCuRiTyPlease do not leave any bags or suitcases unattended at any time, whether inside or outside the session halls.
LiabiLiTyThe Meeting Secretariat and organizers cannot accept liability for personal accidents, loss or damage to private property of participants, either during or directly arising from The 2nd Meeting of the ovarian Club.Participants are expected to make their own arrangements with respect to health and travel.
meeTiNG oRGaNiZeRs
01-12-OC II- part 1.indd 14 22/10/12 12:02:34
The fertilization process of the oocyte, embryo development and implantation in relation to various clinical conditionsDorint Hotel Don Giovanni Prague • Prague, Czech Republic • November 8-11, 2012
23
The fertilization process of the oocyte and embryo development in relation to various clinical conditions
Dorint Hotel Don Giovanni PraGUe Prague, CzeCh rePubliC • November 8-11, 2012
SCIENTIFIC PROGRAM
www.comtecmed.com/OC/2012 • [email protected]
13-21-OC II- part 2.indd 1 22/10/12 12:03:55
The fertilization process of the oocyte, embryo development and implantation in relation to various clinical conditionsDorint Hotel Don Giovanni Prague • Prague, Czech Republic • November 8-11, 2012
14
SCIENTIFIC PROGRAM
14:30-16:30 SESSION 1 Harvesting and Harnessing Human Ovarian stem Cells Supported by an unrestricted grant by IBSA
Chairpersons: Carlos Simón, Spain; Zeev Shoham, Israel; Gerald Schatten, USA
14:30-15:00 Isolation and characterization of OSCs in human Jonathan Tilly, USA
15:00-15:30 Formation of new human follicles from OSCs in vitro Evelyn Telfer, UK
15:30-16:00 Testing genetic integrity of OSC formed oocytes David Albertini, USA
16:00-16:30 Modulation of Mouse Oogonial Stem Cell Fate Determination by Long-term Propagation Dori Woods, USA
16:30-17:00 Coffee Break/ Poster Viewing
17:00-19:00 SESSION 2 tHe mystery Of fertility PreservatiOn
Chairpersons: Sherman Silber, USA; Kenneth Korach, USA
17:00-17:30 The oocytes as the conductor of the reproductive symphony Pasquale Patrizio, USA
17:30-18:00 Directional freezing or vitrification; which child do I prefer? Amir Arav, Israel
18:00-18:30 Vitrification- as applied embryos and ovaries Sherman Silber, USA
18:30-19:00 Oocyte Cryopreservation for Cancer and Deferred Reproduction Nicole Noyes, USA
19:00 OVaRIaN CLuB MEET & GREET
Thursday, November 8, 2012
13-21-OC II- part 2.indd 2 22/10/12 12:03:56
The fertilization process of the oocyte, embryo development and implantation in relation to various clinical conditionsDorint Hotel Don Giovanni Prague • Prague, Czech Republic • November 8-11, 2012
15
SCIENTIFIC PROGRAM
08:30-10:30 SESSION 3 reCruitment, fOlliCular develOPment and OOCyte COmPetenCe Supported by an unrestricted grant by IBSA
Chairpersons: Evelyn Telfer, UK; Jeremy Thompson, Australia; Ariel Hourvitz, Israel
08:30-09:00 Molecular characterization of human folliculogenesis and ovulatory events - from basic research to clinical application Ariel Hourvitz, Israel
09:00-09:30 What granulosa cell- and oocyte-specific aRKO mice can tell us about folliculogenesis and female fertility Aritro Sen, USA
09:30-10:00 CHK1 is involved in SaC satisfaction and preservation of DNa integrity in mouse oocytes Jan Motlik, Czech Republic
10:00-10:30 appropriate meiotic segregation in oocytes: possible practical implications Nava Dekel, Israel
10:30-11:00 Coffee Break/ Poster Viewing
11:00-13:00 SESSION 4 tHe envirOnmental influenCe Of OOCytes and embryOs
Chairpersons: Satish Gupta, India; Patrick Quinn, USA; Maurizio Dattilo, Italy
11:00-11:30 Environmental exposures and gametogenesis: are exposures affecting our reproductive health? Patricia Hunt, USA
11:30-12:00 Late procreation in the main determinant of multiple pregnancies Piergiorgio Crosignani, Italy
12:00-12:30 Environmental action on Ovarian toxicity Kenneth Korach, USA
12:30-13:00 Relationship of telomere length in human gametes and zygotes with semen analysis parameters, sperm DNa fragmentation, smoking status and treatment outcome: What are the clinical implications of telomere length for embryo viability? Geraldine Hartshorne, UK
13:00-13:45 Lunch Break
Friday, November 9, 2012
13-21-OC II- part 2.indd 3 22/10/12 12:03:56
The fertilization process of the oocyte, embryo development and implantation in relation to various clinical conditionsDorint Hotel Don Giovanni Prague • Prague, Czech Republic • November 8-11, 2012
16
SCIENTIFIC PROGRAM
13:45-14:15 new HOrizOns: tHe vOiCe Of tHe industry Company symposium sponsored by Abbott
aBBOTT'S RESEaRCH aCTIVITIES IN IVF
Julian V. Platon, MD, PhD Global Medical Director, Gastrointestinal & Women Health Strategic Medical affairs abbott Products Operations aG, Basel, CH
14:15-15:45 SESSION 5 OOCytes and embryOs: CliniCal relevanCe
Chairpersons: Shevach Friedler, Israel; Denny Sakkas, USA; Marcos Meseguer, Spain
14:15-14:45 In Vitro Maturation does not offer any advantage over current IVF for PCOS patients Samir Hamamah, France
14:45-15:15 alterations in oocyte, embryo and/or endometrium quality in endometriosis: identifying the weak link Dominique De Ziegler, France
15:15-15:45 Ovarian stimulation for IVF, the oocyte and the embryo: possible detrimental effects Esther B. Baart, The Netherlands
15:45-16:15 Coffee Break/ Poster Viewing
16:15-18:15 SESSION 6 biOmarkers: CliniCal relevanCe Endorsed by IVI
Chairpersons: Carlos Simón, Spain; Samir Hamamah, France; Maria Lalioti, USA
16:15-16:35 Polymorphisms as biomarkers of ovarian reserve and oocyte quality Maria Lalioti, USA
16:35-16:55 Cumulus cells as markers of oocyte and embryo quality Emre Seli, USA
16:55-17:15 Clinical relevance of morphokinetics to assess embryo viability Marcos Meseguer, Spain
17:15-17:35 Non invasive metabolomic profiling of embryos using spectroscopy Denny Sakkas, USA
17:35-17:55 use of Comparative Genomic Hybridization (CGH) for embryo assessment. Clinical results Carmen Rubio, Spain
17:55-18:15 Conclusion Carlos Simón, Spain
18:15 OVaRIaN CLuB MEET & GREET
Friday, November 9, 2012
13-21-OC II- part 2.indd 4 22/10/12 12:03:57
The fertilization process of the oocyte, embryo development and implantation in relation to various clinical conditionsDorint Hotel Don Giovanni Prague • Prague, Czech Republic • November 8-11, 2012
17
SCIENTIFIC PROGRAM
08:30-10:30 SESSION 7 CliniCal imPliCatiOn Of iCsi failure Supported by an unrestricted grant by IBSA
Chairpersons: Shlomo Mashiach, Israel; Nicole Noyes, USA; Jonathan Van Blerkom, USA
08:30-09:00 The sperm-egg, fertilization and the embryo: Egg activation - calcium oscillations and outcome in pre and post implantation development Jean-Pierre Ozil, France
09:00-09:30 The mechanisms of mammalian sperm-egg interaction John C. Herr, USA
09:30-10:00 Cell cycle control in human embryos: Why all the aneuploidy? David Albertini, USA
10:00-10:30 Post-transciptional regulations during oocyte-to-zygote transition Petr Svoboda, Czech Republic
10:30-11:00 Coffee Break/ Poster Viewing
11:00-13:00 SESSION 8 metabOliC PrOgramming during tHe PreCOnCePtiOn PeriOd and imPliCatiOns fOr subsequent fetal, neO-natal and adult HealtH
Chairpersons: Ellen Anckaert, Belgium; David Albertini, USA; Carlos Simón, Spain
11:00-11:30 Preconception protein levels and subsequent fetal growth Tom Fleming, UK
11:30-12:00 Cellular disruption within oocytes and early embryos caused by maternal diabetes – basic and clinical implications Kelle H. Moley, USA
12:00-12:30 O-linked glycosylation mediates the hyperglycemic pathology in oocytes and early embryos? Jeremy Thompson, Australia
12-30-13:00 Dietary methyl donors during the preconception period and their influence on subsequent development Kevin Sinclair, UK
13:00-13:45 Lunch Break
Saturday, November 10, 2012
13-21-OC II- part 2.indd 5 22/10/12 12:03:58
The fertilization process of the oocyte, embryo development and implantation in relation to various clinical conditionsDorint Hotel Don Giovanni Prague • Prague, Czech Republic • November 8-11, 2012
18
SCIENTIFIC PROGRAM
13:45-14:15 new HOrizOns: tHe vOiCe Of tHe industry Company symposium sponsored by Ferring
WHy HEaLTH CaRE PROFESSIONaLS aND PHaRMa MuST WORK TOGETHER TO IDENTIFy aND MEET PaTIENTS’ NEEDS
Julian Jenkins, DM, FRCOG Head of Global Medical affairs Ferring International Center Sa, St. Prex, Switzerland
14:15-16:15 SESSION 9 tHe fertilizatiOn PrOCess
Chairpersons: Norbert Gleicher, USA; Gwo-Jang Wu, Taiwan; Jan Motlik, Czech Republic
14:15-14:45 Membrane and cytoplasmic influences on penetration and post penetration development - Can basic science provide markers for the clinical embryologist Jonathan Van Blerkom, USA
14:45-15:15 Role of Chromatin Remodeling Proteins in Chromosome Segregation and the Transmission of aneuploidy in Mammalian Oocytes. Basic research with clinical implications Rabindranath De La Fuente, USA
15:15-15:45 The Minimal Oocyte – or How to construct an artificial egg? what are the requirements for the oocyte to achieve it mission Gerald Schatten, USA
15:45-16:15 Human Tubal Fluid: In Vivo and In Vitro Patrick Quinn, USA
16:15-16:45 Coffee Break/ Poster Viewing
Saturday, November 10, 2012
13-21-OC II- part 2.indd 6 22/10/12 12:03:59
The fertilization process of the oocyte, embryo development and implantation in relation to various clinical conditionsDorint Hotel Don Giovanni Prague • Prague, Czech Republic • November 8-11, 2012
19
SCIENTIFIC PROGRAM
16:45-18:45 SESSION 10 aging
Chairpersons: Dominique De Ziegler, France; Piergiorgio Crosignani, Italy; Zeev Shoham, Israel
16:45-17:15 How androgens and genes affect follicle maturation and ovarian aging Norbert Gleicher, USA
17:15-17:45 How do Oocytes Tell Time? (Oocyte aging and Can the Chronology Sensing Machinery Be Reset) Gerald Schatten, USA
17:45-18:15 Female reproductive aging: new insights into an old problem Mary Herbert, UK
18:15-18:45 The impact of y chromosome like regions of the X chromosome (palindromes and amplicons) on ovarian reserve Sherman Silber, USA
Saturday, November 10, 2012
13-21-OC II- part 2.indd 7 22/10/12 12:03:59
IVF-Worldwide.com is the largest and most comprehensive in-vitro fertilization (IVF)-focused websitefor doctors, embryologists, nurses and social workers.IVF-Worldwide.com has been constructed with a vision of improving patient care by encouragingdiscussion between professionals, advancing research and promoting publication of educationalmaterials.Enjoy the wealth of information offered by IVF-Worldwide. Register to receive our newsletter and stayupdated on new developments in the field of IVF. Tune in to the IVF-Worldwide Blog to read posts byleading experts. Join our Linked In and Facebook group and take part in the dialogue regarding specialtreatments and advance research issues. Enter our Business Directory and learn about medical equipmentmanufacturers.Be part of our community of IVF specialists dedicated to promoting excellence in reproductive medicine.
THE WORLD'S LARGEST IVF DIRECTORYincluding national and international sperm banks
WWW.IVF-WORLDWIDE.COM
www.ivf-worldwide.com Be part of our global network...
IVF-Worldwide.com is built with the vision to give to its members the ability to locateIVF units anywhere in the world and to communicate directly with the unit. In additionIVF-Worldwide.com will be home to a large section of educational material includingrecent publications, abstracts, PowerPoint presentations and newsletters.
13-21-OC II- part 2.indd 8 22/10/12 12:04:01
The fertilization process of the oocyte, embryo development and implantation in relation to various clinical conditionsDorint Hotel Don Giovanni Prague • Prague, Czech Republic • November 8-11, 2012
23
The fertilization process of the oocyte and embryo development in relation to various clinical conditions
Dorint Hotel Don Giovanni PraGUe Prague, CzeCh rePubliC • November 8-11, 2012
SPEAkERS OvERvIEwS
www.comtecmed.com/OC/2012 • [email protected]
(order as per the Scientific Program)
IVF-Worldwide.com is the largest and most comprehensive in-vitro fertilization (IVF)-focused websitefor doctors, embryologists, nurses and social workers.IVF-Worldwide.com has been constructed with a vision of improving patient care by encouragingdiscussion between professionals, advancing research and promoting publication of educationalmaterials.Enjoy the wealth of information offered by IVF-Worldwide. Register to receive our newsletter and stayupdated on new developments in the field of IVF. Tune in to the IVF-Worldwide Blog to read posts byleading experts. Join our Linked In and Facebook group and take part in the dialogue regarding specialtreatments and advance research issues. Enter our Business Directory and learn about medical equipmentmanufacturers.Be part of our community of IVF specialists dedicated to promoting excellence in reproductive medicine.
THE WORLD'S LARGEST IVF DIRECTORYincluding national and international sperm banks
WWW.IVF-WORLDWIDE.COM
www.ivf-worldwide.com Be part of our global network...
IVF-Worldwide.com is built with the vision to give to its members the ability to locateIVF units anywhere in the world and to communicate directly with the unit. In additionIVF-Worldwide.com will be home to a large section of educational material includingrecent publications, abstracts, PowerPoint presentations and newsletters.
13-21-OC II- part 2.indd 9 22/10/12 12:04:06
S-1
ISOLATION AND CHARACTERIZATION OF OSC’S IN HUMAN
Jonathan Tilly, USA
For decades it was believed that mammalian females rely on primordial germ cell
(PGC)-derived oogonia to generate their entire quota of oocytes during embryogenesis, leading to the endowment of a non-renewable pool of oocyte-
containing follicles at birth. However, the recent discovery of mitotically active germ cells, referred to hereafter as oogonial (oocyte-producing) stem cells
(OSCs), in adult mouse and human ovaries opens the prospects that the mammalian oocyte pool is actively replenished at least during early adulthood.
Such a paradigm shift would draw strong parallels to maintenance of adult
spermatogenesis by spermatogonial stem cells (SSCs) in the testes as well as to the continuous production of oocytes during adulthood in less evolved species such as flies and teleost fish. This
presentation will highlight new advances in the field of mammalian OSC biology, including as-yet unpublished observations from our lab regarding the functionality of eggs generated by transplanted
mouse OSCs, as tested in natural mating trials, as well as insights into the signaling pathways that guide
the decisions of self-renewal (proliferation) versus differentiation (meiotic commitment) in OSCs in vitro and in vivo. Lastly, experimental evidence supporting a central role for OSC dysfunction with age to
deterioration of the ovarian reserve, and eventual ovarian failure, will be overviewed.
IN VITRO FOLLICLE FORMATION AND GROWTH FROM
HUMAN OSC’S Evelyn Telfer, UK
Recent work from Jon Tilly‟s group has demonstrated the isolation and
identification of oocyte-producing germline stem cells [oogonial stem cells (OSC)] from ovaries of reproductive age woman. The isolation of
such rare cells from adult human ovaries makes this work significant in
a biological context, providing a model to study human oocyte development at the earliest stages. This presentation will focus on work that our lab has been
conducting in collaboration with Jon Tilly‟s group to characterise the ability of human OSCs to form primordial follicles within a human ovarian cortex culture system and their subsequent ability to grow
within a multi-step culture system developed to support human oocyte growth and development. These
studies demonstrate that new primordial follicles are formed from these OSCs and that the limitation to formation is the somatic cell availability. Our results show that follicles formed from OSC‟s are capable of
growth to multi-laminar stages and significant oocyte growth can be achieved. Whilst the in vivo significance of these cells has yet to be determined, our system will facilitate their characterisation and
allow us to define the potential of OSC derived putative oocytes in vitro.
TESTING GENETIC INTEGRITY OF OSC FORMED OOCYTES David Albertini, USA
With several reports now in the literature having claimed to have made oocyte-like cells from stem cells of various sources, an urgent
call for quality control measures is now upon us before clinical applications can be realized. From a cell cycle point of view, stem cells
and oocytes have a checkered history owing to their remarkable predisposition towards aneuploidy, just one of the many forms of
genetic instability that have been well characterized in human
oocytes, embryos, and ES cells. The need for methodology that will allow the assessment of genetic integrity on oocyte-like cells will be discussed in the context of liabilities
obtained from meiotic re-entry and or periods of amplification at a somatic cell level prior to transformation into gametic progenitors.
S-2
LONG-TERM IN VITRO CULTURE OF MOUSE OOGONIAL STEM
CELLS INFLUENCES CELL FATE DETERMINATION
Dori C. Woods, USA
Recent studies have reported that adult mouse and human ovaries contain a rare population of oogonial stem cells (OSCs) which have the
ability to generate new oocytes during reproductive life. Among the
properties of OSCs is the ability to self-renew and produce daughter cells that undergo differentiation into oocytes. Like their male counterparts
(spermatogonial stem cells or SSCs), OSCs can be established as propagating cells in culture, and in mice such cultured cells returned to
adult mouse ovaries produce developmentally competent eggs. Studies of
mouse SSCs maintained ex vivo have shown that a subpopulation of the cells undergoes a transformation process producing testicular multi-
potent adult germline stem cells (maGSCs), as defined by a number of endpoints including tumor formation following transplantation in vivo. While freshly-isolated mouse OSCs exhibit a single fate
(oocyte formation) with no capacity to generate tumors, prolonged ex-vivo expansion of these mouse cells produces a multi-potent phenotype similar to that described for mouse SSCs cultured ex vivo, as
revealed by the in vivo tumor formation assay. Interestingly, OSCs isolated from ovaries of reproductive
age women do not undergo this multi-potential transformation, even after long-term propagation for many months, with 100% of the cell lines tested from multiple subjects failing to show tumorigenic
potential in vivo. Thus, while the change in cell fate determination towards multi-potentiality associated with long-term culture of OSCs is mouse-specific (as appears to be the case for SSCs as well), these
studies nonetheless provide a defined in vitro model system to help elucidate events and pathways
responsible for governing germline identity and stem cell potentiality.
THE OOCYTES AS THE CONDUCTOR OF THE REPRODUCTIVE SYMPHONY
Pasquale Patrizio, USA
Human oocytes represent one of the most important variables for the success
of IVF. Since inception of IVF and despite progress in clinical and laboratory protocols, the rate of live birth per retrieved oocyte is still disappointingly low
(about 5%). The majority of oocytes obtained during IVF are either chromosomally or genetically abnormal. A number of new, non-invasive,
technologies aiming at deciphering the transcriptome of the cumulus cells and
the associated oocyte, the follicular fluid and oocyte culture media content, have the potential to improve identification of competent oocytes.
Understanding genetic pathways important for oocyte intrafollicular maturation and for the completion of meiotic processes would enable the selection of oocytes (and
subsequently embryos) with the greatest reproductive potential and would represent the next
breakthrough in ART.
S-3
DIRECTIONAL FREEZING OR VITRIFICATION; WHICH CHILD DO I
PREFER? Amir Arav, Israel
Directional freezing is a technique which permits accurate control of the heat transfer and ice crystal propagation velocity during the freezing process. In the last
20 years we applied this technique on sperm of different species, oocytes embryos, tissue and even whole organs freezing and we published our achievements.
Vitrification is becoming the golden standard for oocytes and embryos cryopreservation since the method of minimal volume ("minimum drop size") which
allows reducing cryoprotectant concentration to non toxic levels, developed by us. I will demonstrate the
state of the art in both methods and speculate on future applications in the reproduction field.
VITRIFICATION AS APPLIED TO EMBRYOS AND OVARIES
Sherman Silber, USA
The aim of this lecture is to summarize the state-of-the-art of embryo and
ovarian tissue cryopreservation with vitrification. Ten of ten fresh ovary transplants were successful, resulting in twelve healthy
babies in eight of the ten recipients. Recipients always reinitiated ovulatory
menstrual cycles and normal Day 3 serum FSH levels by 4-1/2 months. Grafts of just modest portions of ovarian tissue have lasted more than 7 years.
The same surgical techniques were then applied to frozen ovary tissue transplants, up to 14 years after the ovary had been frozen, all resulting in
normal ovulation and a total of 30 healthy babies worldwide, whereas, in no
cancer patients have any babies thus far resulted from egg freezing. Slow freeze has resulted in only a 50% loss of oocytes, and vitrification has resulted in no loss. With
vitrification, embryos can be frozen with impunity, whereas with slow freeze (like with ovarian tissue) there is some viability loss. Vitrification may thus eventually obviate the growing worldwide epidemic of
female age-related decline in fertility, and even could eliminate menopause.
OOCYTE CRYOPRESERVATION FOR CANCER AND DEFERRED REPRODUCTION
Nicole Noyes, USA
In 2012, more than a million new female cancers will be diagnosed worldwide;
~10% in women of reproductive age. This, combined with a global delay in childbearing threatens the ability of women to reproduce. Recent advances in
cryobiology have resulted in >1500 live births as a result of oocyte cryopreservation, with pregnancy/live-birth rates matching those of conventional
IVF in some centers, thus, providing the option for autonomous fertility
preservation (FP) and the chance for successful reproduction at a time more conducive to childbearing. Dr. Noyes‟s lecture will cover oocyte cryopreservation topics such as treatment indications an
modifications, special considerations, and successes to date.
S-4
MOLECULAR CHARACTERIZATION OF HUMAN FOLLICULOGENESIS AND
OVULATORY EVENTS - FROM BASIC RESEARCH TO CLINICAL APPLICATION
Ariel Hourvitz, Israel
Ovarian follicular development and ovulation in mammals is a complex and highly
regulated process. Most advances in the understanding of the ovulatory process have come from animal models, mainly the rodent. These experimental findings
should be validated in human study. IVM/IVF procedures allow us to obtain follicular fluid and granulosa cells from
follicles in different developmental stages. Using the cells and fluids obtained in
IVM/IVF procedures allowed us to characterize human ovulatory gene expression during antral folliculogenesis and ovulation, examine gene expression in luteinized and non-luteinized
granulosa cells in vivo and in vitro and to use cumulus granulosa cells genes as biomarkers for oocyte and embryo maturity and competence.
Using global transcriptome sequencing we were able to generate a library of genes regulated during
cumulus expansion and oocyte maturation processes. Analysis of these genes, will allow us to identify new important genes involved in cumulus oocyte complex maturation and cumulus expansion, and may
contribute to improve the process of in vitro maturation of immature oocytes aspirated during IVM cycles. We will present an extensive review of the currently available literature in this field together with
our preliminary results.
WHAT GRANULOSA CELL- AND OOCYTE-SPECIFIC ANDROGEN RECEPTOR KNOCKOUT (ARKO) MICE CAN TELL US ABOUT
FOLLICULOGENESIS AND FEMALE FERTILITY
Aritro Sen, USA
Androgens have traditionally been considered detrimental to women‟s health and associated with deregulated ovarian function and infertility.
However lately, many clinical studies have reported benefits of androgen priming prior to IVF cycles in women with decreased ovarian reserve.
Intriguingly, through the generation of a granulosa cell (GC)- and an
oocyte-specific androgen receptor (AR) knockout (ARKO) mouse model, we have recently pioneered a new concept that critical androgen actions in GCs, but not in the oocyte are absolutely essential for
normal ovarian function and female fertility. Our studies indicate that ARs expressed in GCs control pre-antral follicle growth and development to antral follicles, while preventing follicular atresia. However, to
date, the underlying mechanism of AR actions in the ovary has remained elusive. It is well established
that androgen functions are mediated by both “genomic” and “membrane-initiated” actions of ARs. Using our GC-specific ARKO mouse model, we have now uncovered two novel regulatory pathways that
may account for the AR actions in GCs. First we have found that ARs regulate the expression of a micro-RNA (miR) that may contribute to androgen-induced follicular survival. The expression of this miR in GCs
requires a synergistic action between the nuclear and extra-nuclear AR signaling. Secondly, ARs exclusively through a non-genomic pathway augment FSH actions during follicular development. This
lecture will discuss recent findings of AR actions in normal follicular development and how the studies in
GC-specific ARKO mouse model help in understanding some of the recent clinical data regarding androgen effects in infertility treatment.
S-5
CHK1 IS INVOLVED IN SAC SATISFACTION AND PRESERVATION OF DNA
INTEGRITY IN MOUSE OOCYTES Jan Motlik, Czech Republic
We have shown that Check point kinase 1 (CHK1) is involved in timely correct spindle assembly checkpoint (SAC) satisfaction but it is not SAC component. More
importantly, CHK1 deficient oocytes have higher level of DNA damage leading to chromosome breaks and loss of DNA fragments in anaphase I. Female conditionally
deficient for CHK1 in oocytes are highly subfertile and more often completely unfertile.
APPROPRIATE MEIOTIC SEGREGATION IN OOCYTES: POSSIBLE PRACTICAL IMPLICATIONS
Nava Dekel, Israel
Meiosis in oocytes includes two asymmetric cell divisions. The first meiotic division,
during which the homologous chromosomes segregate, is particularly error prone, leading to aneuploidy and genetic malformations. Completion of this division,
characterized by the formation of the first polar body (PBI), is fully dependent on proteasomal protein degradation and the subsequent CDK1 inactivation. We
identified the polyubiquitin signal that mediates proteasomal action at this stage of
meiosis and characterized the role of CDK1 inactivation during PBI extrusion. Shedding light on the complexity of meiosis these results may potentially contribute to our understanding of unfaithful
chromosome segregation.
ENVIRONMENTAL EXPOSURES AND GAMETOGENESIS: ARE EXPOSURES AFFECTING OUR REPRODUCTIVE
HEALTH? Patricia Hunt, USA
Experimental studies in rodents suggest that environmental endocrine disruptors impact the developing reproductive tract of
both males and females. In the female, at least three distinct stages of egg development are vulnerable, and it appears that
exposures can affect both reproductive success and longevity. In the male, exposure to environmental estrogens during testis development causes a drop in testis
size, a reduction in sperm counts, and permanently alters the process of spermatogenesis in the adult
testis. Taken together, experimental studies suggest that BPA adversely impacts gametogenesis and fertility in both sexes, and more recent findings from studies in the rhesus monkey make it likely that
these effects extend to humans.
S-6
LATE PROCREATION IN THE MAIN DETERMINANT OF MULTIPLE
PREGNANCIES Piergiorgio Crosignani, Italy
Monozygotic twins arise from the fertilization of a single oocyte, with the resulting embryo splitting during early development to form two separate
embryos. In contrast, dizygotic twins result from the fertilization of two separate oocytes, which subsequently develop as two separate embryos. The dizygotic
twinning rate varies in different populations and its incidence has risen in the last 30 years on account of the current tendency to postpone childbearing and the
increased use of ovarian stimulation.
The risk of dizygotic twinning is linked to the postponement of childbearing, as increased maternal age is associated with a decline in ovarian feedback capacity and elevations in FSH. Therefore, il older
women, there is a tendency towards multile follicular development and an increased prevalence of twinning. As higher numbers of women delay reproduction, for understandable social reasons, an
additional 5-8 twins per 1000 births will be born every year.
On the other hand pharmacologic ovarian stimulation induces the simultaneous growth of multiple follicles, leading to the ovulation of more than one egg, and hence, multiple pregnancies. The milder
ovarian stimulation used in IUI cycles and the choice of single embryo transfer for IVF cycles can largely prevent iatrogenic twinning.
On the contrary there seems to be no way to stop the increase in risk of natural twinning due to the current widespread choice of late procreation.
ENVIRONMENTAL ACTION ON OVARIAN TOXICITY Kenneth Korach, USA
Estrogen receptors (ER) are thought to play a crucial role in development, reproduction and normal physiology. We produced lines of mice homozygous for
phenotype occurs developmentally due to elevated LH and can be reversed by a
GnRH antagonist similar to PCOS. Ovarian gonadotropin receptor levels, serum
breeding studies and superovulation show arrested
function similar to clinical LUF syndrome. Granulosa cell cultures indicate poor target gene stimulation in
a/b knockout shows a unique ovarian phenotype of transdifferentiation of granulosa to sertoli cells and
altered gene expression pattern, suggesting that both ER signaling mechanisms must be functional in order to maintain the proper differentiation state of the granulosa cells and oocyte developmental
viability.
S-7
RELATIONSHIP OF TELOMERE LENGTH IN HUMAN GAMETES AND
ZYGOTES WITH SEMEN ANALYSIS PARAMETERS, SPERM DNA FRAGMENTATION, SMOKING STATUS AND TREATMENT OUTCOME:
WHAT ARE THE CLINICAL IMPLICATIONS OF TELOMERE LENGTH
FOR EMBRYO VIABILITY? Geraldine Hartshorne, UK
This paper will present new data on telomere length in human individual
spermatozoa, oocytes at different stages of maturation, and both male and female pronuclei in newly formed zygotes. Telomere lengths in sperm
samples donated by an unselected group of men have been tested for
relationships to sperm DNA fragmentation and routine semen analysis criteria and analysed in relation to the men‟s smoking status and eventual outcome of treatment.
Sperm DNA fragmentation was related to clinical parameters, however telomere length was not. We show that telomere length in human oocytes reduces with maturation, and that mature oocytes and
female pronuclei have similar length telomeres, as do sperm and male pronuclei from the same donor.
Telomeres in sperm and male pronuclei were, on average, significantly shorter than those in oocytes and female pronuclei.
IN VITRO MATURATION DOES NOT OFFER ANY ADVANTAGE OVER CURRENT IVF FOR PCOS PATIENTS
Samir Hamamah, France
Patients suffering from PCOS benefit from assisted reproduction techniques (ARTs) adopted to induce multiple follicle maturation under controlled ovarian
stimulation (COS). Although sufficient oocytes are usually retrieved for IVF, there
are accumulated data suggesting that the oocyte developmental competence is altered in PCOS. To date, the gene expression profile of CCs from women with
PCOS has been rarely investigated. The aim of this lecture is (i) to establish the gene expression profile of human CCs at different stages of oocyte maturation
following in vivo and in vitro oocyte Maturation and (ii) to investigate the gene expression profile of
human CCs isolated from mature metaphase II oocytes from a homogeneous group (age, weight and similar COS protocol) of patients with or without PCOS. we report the down-regulation of genes involved
in cumulus expansion (TNFAIP6, PTGS2 and PTX3) as well as of genes related to oocyte maturation, including several EGF-like growth factors (EREG, AREG and BTC) in CCs from in vitro matured oocytes in
comparison with CCs from in vivo matured oocytes. On the other hand, In PCOS CCs, 65% of genes related to the TGFb signalling pathways were down-regulated, including several members of the TGFb
superfamily (INHBC, INHBB, TGFB1 and TGFB1I1), type II TGFb receptors and their targets SMAD1/5,
as well as the TGFb receptor III. Also, estrogen receptor signalling was altered in CCs from the PCOS group compared with the control group. In conclusion, the comparison of the gene expression profiles
of CCs from PCOS and non-PCOS patients suggests that, in women with PCOS, CC competence is strongly affected. Specifically, major signalling pathways that play a key role in the gradual acquisition
of developmental competency by the oocyte (particularly the TGFb and the estrogen receptor signalling
cascades) are altered in CCs from women with PCOS. Moreover, many genes, the expression of which is influenced by environmental and extra-ovarian factors, are also deregulated in PCOS CCs and their
alteration may play a role in PCOS pathophysiology.
S-8
ALTERATIONS IN OOCYTE, EMBRYO AND/OR ENDOMETRIUM
QUALITY IN ENDOMETRIOSIS: IDENTIFYING THE WEAK LINK Dominique De Ziegler, France
Endometriosis – an ailment of unknown origin – causes pain and infertility. Women suffering from endometriosis perform less well in assisted reproductive
technologies (ART). From the sum of existing reports, we know that the responses to controlled ovarian stimulation (COS) and embryo implantation
rates are diminished in endometriosis. Remarkably, all the studied alterations of the eutopic endometrium – notably, CYP-19 activation and resistance to P4
– are normalized by a temporary suppression of ovarian function. ART data
indicate that the timely use of GnRH-a or OC normalizes embryo implantation in endometriosis. In conclusion, the responses to COS are altered in ovarian
endometriosis, but without alteration in ART outcome. These alterations can be normalized by timely use of OC or GnRH-a, allowing to achieve similar ART outcome despite poor ovarian response to COS.
OVARIAN STIMULATION FOR IVF , THE OOCYTE AND THE
EMBRYO: POSSIBLE DETRIMENTAL EFFECTS Esther B. Baart, The Netherlands
We have previously demonstrated that mild stimulation reduces the number of oocytes retrieved, but significantly increases the proportion of
chromosomally normal embryos. By now, other studies have observed a similar correlation between attenuation of the ovarian response and
euploidy. Taken together, these observations suggest that selection of
better quality embryos may be achieved by applying milder stimulation approaches, by allowing only the most mature follicles to develop. Alternatively, the observed
differences may be due to a direct effect of the GnRH analogue or gonadotrophin used. This presentation will explore possible underlying mechanisms and implications for embryo quality and
selection.
POLYMORPHISMS AS BIOMARKERS OF OVARIAN RESERVE AND OOCYTE QUALITY
Maria Lalioti, USA
Optimal ovarian function is necessary for gonadal development and
maturation at puberty and for gamete production during the reproductive phase of life and therefore for fertility. Inactivating mutations in critical genes,
such as the FSH-beta, FSH receptor (FSHR), LH-beta, and LH receptor (LHR), cause infertility, while activating mutations can cause ovarian
hyperstimulation. Unlike these mutations that define the two extremes of the
spectrum, single nucleotide polymorphisms (SNPs) that result in amino acid substitutions within the promoter or coding regions have been associated with
variability in ovarian response to FSH, Polycystic Ovary Syndrome, and ovarian cancer. Moreover, genome-wide studies have pinpointed associations with
SNPs in several genes. However, each one of the SNPs has only a small contribution to the phenotype, attesting the multifactorial nature of the problem.
Pharmacogenomics is the branch of pharmacology that aims to study the influence of genetic variability
to drug efficiency or toxicity and ultimately, optimize therapy to suit the patient's genotype. Pharmacogenomics profit immensely from the vast advances in the study of the genome, which includes
population distribution of polymorphisms, and technological advances, which make patient genotyping easy and affordable. However, it is imperative to study the change that each SNP confers to the function
in the molecular level, because this will be the key to unravel the optimal match to a drug.
This lecture will summarize the findings linking genome variation to ovarian reserve and oocyte quality.
S-9
CUMULUS CELLS AS MARKERS OF OOCYTE AND EMBRYO QUALITY
Emre Seli, USA
The high success rates seen following in vitro fertilization (IVF) are
attained in many cases through the simultaneous transfer of multiple embryos at the expense of multiple pregnancies. Multiple pregnancies,
in turn, are associated with significant morbidity and mortality, primarily due to their propensity to result in preterm birth. Consequently,
decreasing multiple gestations while maintaining or improving overall pregnancy rates remains the most
significant contemporary goal in the treatment of infertility. In order to achieve this goal, an improvement over our current embryo assessment strategies (largely based on embryo morphology and
cleavage rates) would be useful. Oocytes are in close contact with granulosa/cumulus cells throughout folliculogenesis. Genes exclusively
expressed in oocytes (such as GDF9 and BMP15) are required for normal follicle growth and cumulus
function. Therefore, (1) cumulus cell transcriptome is likely to reflect oocyte quality and viability, and (2) analysis of cumulus cells in women undergoing IVF could potentially be used as a non-invasive approach
to assess oocyte and embryo viability. Within this context, independent investigators have identified specific cumulus cell transcripts associated with oocyte or embryo viability. The clinical validation of
these biomarkers in IVF setting is awaited.
CLINICAL RELEVANCE OF MORPHOKINETICS TO ASSESS EMBRYO VIABILITY
Marcos Meseguer, Spain
Time-lapse observation presents an opportunity for optimizing this embryo
selection based on morphological grading as well as providing novel kinetic parameters, which may further improve accurate selection of viable embryos.
We are presenting the largest set of transferred embryos after time-lapse analysis and thus a novel opportunity to correlate morphokinetic parameters
to implantation and ongoing pregnancy. We have generated and evaluated a
tool for the selection of viable embryos based on the exact timing of embryo development events together with morphological patterns by using an
automatic time-lapse system to monitor embryo development. We have elaborated a hypothesis, trying to elucidate whether time-lapse monitoring system together
with embryo selection by morphokinetics is able to improve reproductive outcome. To undergo this
objective we compared the result of an incubator with a built-in time-lapse video system (TMS) to our standard procedure involving normal incubators (SI) and sequential assessment by microscopy. The
study employs logistic regression model to compare the clinical pregnancy for incubations in the TMS with incubations in a SI. Ultimately, several variables were evaluated as confounding factors (CF) that
could possibly affect the outcome. The analysis revealed that TMS had a significant positive impact on
chance of clinical pregnancy. Our intention is to calculate and demonstrate the extent of the positive impact of TMS on pregnancy.
Possible explanations for the observed increase could be : i) strictly controlled conditions, ii) reduced handling, iii) occasional observation of abnormal cleavages ; or iv) selection by morphokinetics related
to embryo implantation.
S-10
NON INVASIVE METABOLOMIC PROFILING OF EMBRYOS USING
SPECTROSCOPY
Denny Sakkas, USA
Although the clinical IVF Laboratory has undergone numerous radical changes in the past 30 years, improving the ability to quickly identify the best single
embryo for transfer remains a critical goal. A number of technologies
including the non-invasive measurement of glucose, lactate, pyruvate and amino acids have been present for over 20 years but were not adapted to
clinical practice. The assessment of the embryo and correlation to viability using, genomic and proteomic profiling, and more recently, analytical
examination of the embryonic metabolome has shown greater promise.
Metabolomic profiling of embryo culture media using optical and non-optical spectroscopy associated with bioinformatics is providing greater insight into
the identification of embryos with increasing reproductive potential. Numerous instrumentation techniques examining the metabolome including, Near Infra Red, Raman, Nuclear Magnetic Resonance
and Mass Spectroscopy will be discussed. The pitfalls and benefits of their development and clinical results will be presented showing that although some technologies may show initial promise there global
clinical application can still be hindered with numerous hurdles. In the next decade the IVF laboratory
will be a very different location featuring automated embryo culture and imaging systems and a range of technologies that will allow the possibility of both invasive and non-invasive single embryo profiling to
more accurately assess which embryo will lead to a normal live birth.
USE OF COMPARATIVE GENOMIC HYBRIDIZATION (CGH) FOR EMBRYO ASSESSMENT. CLINICAL RESULTS
Carmen Rubio, Spain
Preimplantation Genetic Diagnosis (PGD) is offered in many IVF
centres to improve the reproductive outcome of specific groups of patients. PGD is used to discard affected embryos in carriers of
monogenic diseases and structural chromosome anomalies. Preimplantation Genetic Screening (PGS) is a variant of PGD applied
to the screening of numerical chromosome anomalies in couples
with normal karyotype, but with infertility problems. Current indications for PGS are: advanced maternal age (AMA), recurrent miscarriage (RM), repetitive implantation failure (RIF), and severe male factor
infertility (SMF). In PGS programs, the technique most widely employed for the cytogenetic analysis of blastomeres has been fluorescence in situ hybridization (FISH) for a selected panel of chromosomes.
Using FISH, prospective randomized trials (RCT) concluded that PGS should not be recommended in AMA patients. Other authors have argued that there are some important methodological pitfalls in the
published RCTs, such us patients´s inclusion criteria, the embryo biopsy procedure, embryo culture
conductions as well as the type of genetic analysis performed. It has been proposed that higher benefits would be reached if the whole set of chromosomes could be tested. The best approach seems to be
array-CGH, which would offer the most complete analysis of the embryo, giving information about all 24 chromosomes. In this presentation, we will present current data with array-CGH analysis for different
indications. In general using this technology pregnancy rates per transfer in our clinical programs has
increased to over 60% for all PGS indications, including advanced maternal age with day-3 embryo biopsy. The experience of other s groups with blastocyst biopsy will be also introduced.
S-11
THE SPERM-EGG, FERTILIZATION AND THE EMBRYO: EGG
ACTIVATION - CALCIUM OSCILLATIONS AND OUTCOME IN PRE AND POST IMPLANTATION DEVELOPMENT
Jean-Pierre Ozil, France
There is compelling evidence that the earliest stages of fertilization in
mammalian eggs are sensitive to perturbation arising from in vitro conditions. Alterations at the adult age, such as body size, hypertension or
organ: body-weight ratios reflect some hidden mechanisms that are imprinted in the genome in the early stages. The linkage between very early
quantitative changes in egg metabolism and post-natal effects is still poorly
understood. In mammals, fertilization triggers various regimes of Ca2+ oscillations that stimulate the egg metabolism more or less. The variability and the enslavement of the redox potential within the
process of ATP synthesis makes it difficult to discriminate specific impacts of the egg redox and energetic profiles on offspring health. To overcome such difficulties we take the advantage of the
zygote's period of transcriptional inactivity to handle egg functioning solely by changing the composition
of the culture media. We used various carbohydrate compositions to vary the redox potential and the energetic metabolism differently but only during the pronuclear stage. The results show that the adult
weight can be up or down regulated by manipulating the redox potential but only when the activity of the mitochondria is maintained high for a few hours during the PN stage. Therefore, minute
manipulation of the egg metabolism will make it possible to identify the metabolic sensor(s) that orient(s) the developmental processes and program(s) the adult phenotype during egg activation.
THE MECHANISMS OF MAMMALIAN SPERM-EGG INTERACTION
John C. Herr, USA
Molecular mechanisms by which fertilization competent acrosome-reacted sperm bind to the oolemma remain an area of great interest. To identify
oolemmal binding partner(s) for sperm acrosomal ligands, affinity panning was performed with mouse oocyte lysates using sperm acrosomal protein,
SLLP1 as a target. An oocyte specific membrane metalloproteinase, SAS1B
(Sperm Acrosomal SLLP1 Binding Protein [a.k.a. ovastacin]; encoded by the ASTL gene), was identified as a SLLP1 binding partner. SAS1B has 6 splice
variants, each containing a zinc binding active site and a putative transmembrane domain, with signal peptides in three variants, resulting in
protein microheterogeneity in the oocyte. SAS1B transcripts were ovary
specific. SAS1B protein was first detected in early secondary follicles in day 3 ovaries. Immunofluorescence localized SAS1B to the microvillar oolemma of M2 oocytes. After fertilization,
SAS1B decreased on the oolemma and became virtually undetectable in blastocysts. In transfected CHO-K1 cells SAS1B localized to the surface of unpermeabilized cells. Recombinant and native SLLP1 co-
localized with SAS1B to the microvillar domain of ovulated M2 oocytes. Molecular interactions between
mouse SLLP1 and SAS1B were demonstrated by surface plasmon resonance, far-western, yeast two-hybrid, recombinant- and native- co-IP analyses. SAS1B bound to SLLP1 with high affinity. SAS1B had
protease activity, and SAS1B protein or antibody significantly inhibited fertilization. SAS1B knockout female mice showed a 34% reduction in fertility. SAS1B-SLLP1 is one of the few sperm-egg binding
partner pairs where both the oolemma and intra-acrosomal compartment proteins are known. Because SAS1B appears to be restricted among all normal tissues to growing oocytes in secondary and
subsequent follicular stages, and because SAS1B appears on the oolemma, consideration has been
given to SAS1B as a candidate female contraceptive drug target. A cell model will be described for screening immunotoxin biological drugs targeted to SAS1B.
S-12
CELL CYCLE CONTROL IN HUMAN EMBRYOS: WHY ALL THE
ANEUPLOIDY? David Albertini, USA
Cell cycle checkpoints in normal tissues serve to maintain genetic
integrity so as to eliminate progeny carrying imbalanced chromosome numbers or damaged DNA. This talk will focus on the propensity for
human embryos to sustain levels of aneuploidy during preimplantation development without compromising the developmental potential of
the conceptus unless it bears extreme cases of genetic imbalance. When considered in the context of a DNA damage checkpoint, it
becomes apparent that human embryos have a limited capacity to repair DNA double strand breaks of
either maternal or paternal origin.
POST-TRANSCIPTIONAL REGULATIONS DURING OOCYTE-TO-ZYGOTE TRANSITION
Petr Svoboda, Czech Republic
In mouse, a major portion of time during the oocyte-to-zygote transition
occurs in the absence of transcription, and thus depends on post-transcriptional control of the maternal mRNA pool synthesized during oocyte
growth. Many maternal mRNAs are stored in the cytoplasm and are translationally inactive. In somatic cells, the translationally repressed mRNAs
are targeted to different RNA granules, such as stress granules or
Processing bodies (P-bodies). P-bodies are cytoplasmic foci enriched in mRNA-destabilizing proteins, translational repressors and other RNA binding
proteins, and microRNAs (miRNAs). This lecure will provide an overview of the regulation of maternal mRNA storage, recruitment, and degradation in
the mouse model system. A particular attention will be paid to behavior of RNA binding proteins during acquisition of developmental competence in fully-grown GV oocytes and to
induction of maternal mRNA degradation.
PRECONCEPTION PROTEIN LEVELS AND SUBSEQUENT FETAL
GROWTH Tom Fleming, UK
Our research concerns the interaction between environmental factors and early
embryos and oocytes, both in vivo and in vitro using rodent models. These interactions include those mediated through the quality of maternal diet and
health status in vivo and the conditions of in vitro culture as used in IVF
treatment. Our work has shown that poor diet or sickness or suboptimal culture conditions can induce developmental plasticity leading to long-term phenotypic
effects ultimately increasing disease risk in adult life. These effects concern the cardiovascular, metabolic and immune system functioning in particular.
Concerns associated with an adverse periconceptional environment will be discussed including
consideration of developmental mechanisms of induction and propagation of early programming.
S-13
CELLULAR DISRUPTION WITHIN OOCYTES AND EARLY EMBRYOS
CAUSED BY MATERNAL DIABETES – BASIC AND CLINICAL IMPLICATIONS
Kelle H. Moley, USA
The negative impact of obesity on reproduction and pregnancy outcome is
well known, but the mechanisms and time course responsible for developmental failure remain unclear. The high fat diet induced mouse
model for obesity has identified altered mitochondrial activity as one of the mechanisms of obesity-associated reproductive failure. Our data confirm
that maternal obesity adversely affects oocyte mitochondrial morphology
and function. In addition, mice maintained on a high-fat diet produce oocytes with meiotic spindle and chromosome alignment abnormalities, which lead to aneuploid embryos. Finally, embryos from high-fat
fed obese mice that developed normally to the blastocyst stage and are transferred into non-obese dams experience growth retardation and brain abnormalities in the resulting fetuses, demonstrating that
the initiating defect occurred earlier than the blastocyst stage, possible in the oocyte. Our results
suggest that reduced fertility in obese females is, at least in part, oocyte specific. Further studies are needed to elucidate the reversibility of this phenomenon and whether these defects in mitochondrial
energy metabolism are carried over to the next generation .
O-LINKED GLYCOSYLATION MEDIATES THE HYPERGLYCEMIC PATHOLOGY IN OOCYTES AND EARLY EMBRYOS?
Jeremy Thompson, Australia
Perturbations in the homeostasis of the maternal environment during the peri-
conception period are known to cause alterations to subsequent fetal growth and health of offspring. Maternal peri-conception hyperglycaemia, especially
as a result of obesity-induced insulin resistance leading to Type II diabetes, is one such perturbation known to have these effects. However, the causal
pathways leading to this developmental programming are only now being
examined and understood. Hyperglycaemia is known to cause up-regulation of a relatively minor glucose metabolic pathway, the hexosamine-biosynthesis
pathway, the activity of which is also essential for the process of cumulus expansion. However, a consequence of hyperglycaemic induction of this pathway is the up-regulation of
a protein post- -O-linked glycosylation, of specific target proteins. This
-O-linked glycosylation can change protein function, leading to changes in cellular function. These concepts will be developed in the
presentation, and potential clinical therapies for the treatment of maternal hyperglycaemia will also be -O-linked glycosylation.
S-14
DIETARY METHYL DONORS DURING THE PRECONCEPTION
PERIOD AND THEIR INFLUENCE ON SUBSEQUENT DEVELOPMENT
Kevin Sinclair, UK
Compelling evidence exists, both from epidemiological studies in
humans and direct interventionist studies in animals, to indicate that many non-communicable diseases of adulthood originate from
aberrant developmental events that occur in utero. Emerging evidence indicates that maternal malnutrition around the time of
conception can predispose offspring to metabolic and cardiovascular diseases in later life. Studies at
Nottingham focus on the peri-conceptional period and consider the effects of maternal nutrition with an emphasis on one-carbon metabolism and epigenetic programming of offspring health. Studies extend
from rodents to large animals, and utilize embryonic and somatic cells and tissues of human origin. We have demonstrated that physiologically relevant reductions in specific dietary B-vitamins (i.e. B12,
folate) and methionine to intending mothers (sheep) can epigenetically modify DNA methylation in their
progeny, leading to adult offspring with elevated blood pressure, exhibiting signs of „metabolic syndrome‟; effects most pronounced in male offspring. Parallel studies in the rat reveal common
phenotypic effects which were also male specific. Our more recent studies have considered the effects of folate deficiency in women during IVF. Similar phenotypic effects, with respect to ovarian responses
to gonadotrophin treatments, to that observed in sheep were reported. On-going studies in sheep using MBD-Seq are attempting to identify those loci associated with hypertension and insulin resistance in
offspring. Future studies will focus on the genetics of one-carbon metabolism and the sexually dimorphic
phenotypes observed.
MEMBRANE AND CYTOPLASMIC INFLUENCES ON
PENETRATION AND POST PENETRATION DEVELOPMENT-- CAN BASIC SCIENCE PROVIDE MARKERS FOR THE CLINICAL
EMBRYOLOGIST Jonathan Van Blerkom, USA
The molecular architecture of the human oocyte plasma membrane that is consistent with normal fertilization is shown in this presentation to be
organized into unique lipid-raft microdomains containing molecules involved in sperm attachment/docking and penetration. These
microdomains are subject to different modes of cytoplasmic regulation
and fertilization competence is a function of their distribution and density. The function of certain fertilization-associated lipid raft microdomains is dependent upon the bioenergetic state of the subjacent
cytoplasm, with ATP levels regulated directly by the magnitude of the membrane potential across the inner membrane in mitochondrial localized in the subplasmalemmal cytoplasm. Dynamic imaging of
sperm interactions with the oolemma revealed that one type of lipid raft microdomain is likely
responsible for the cessation of sperm head motion at the docking site. Cessation of motion is necessary for robust membrane binding between oolemma and sperm membrane and is a prerequisite for
membrane fusion and penetration. This step involves lipid raft microdomains enriched in the tetraspanin membrane protein CD9, which is exposed following the cessation of motion. Studies of failed
interactions between sperm and oolemma in morphologically normal MII human oocytes have identified specific causes of sperm binding and penetration failure that can be attributed to specific phenotypes of
lipid microdomain organization that (i) are cohort-specific, (ii) account for failure of sperm to attach to
the oolemma, and (iii) can be related to both the protocol of ovarian hyperstimulation and maternal reproductive age. Present findings indicate that live cell imaging with developmentally benign
fluorescent-tagged lipid microdomain reporters could be used to identify fertilization competent phenotypes for fertilization, and is already effective in diagnosing causes of unexpected fertilization
failures after conventional IVF cycles with no male factor and with morphologically normal MII oocytes.
S-15
ROLE OF CHROMATIN REMODELING PROTEINS IN CHROMOSOME
SEGREGATION AND THE TRANSMISSION OF ANEUPLOIDY IN MAMMALIAN OOCYTES. BASIC RESEARCH WITH CLINICAL
IMPLICATIONS
Rabindranath De La Fuente, USA
Transmission of an abnormal chromosome complement, a condition called aneuploidy is a major cause of congenital birth defects and early pregnancy
loss. Human embryos are particularly susceptible to aneuploidy, which in the majority of cases is due to abnormal chromosome segregation in the oocyte.
The molecular mechanisms involved in this process are not known.
Chromatin configuration in the nucleus or germinal vesicle (GV) of mammalian oocytes undergoes dynamic epigenetic modifications during oocyte growth. A crucial
developmental transition at the culmination of oogenesis, large-scale chromatin remodeling in the GV is essential to confer the female gamete with meiotic and developmental potential. Using several models
for the experimental manipulation of chromatin structure and function, our current work seeks to
determine the signaling pathways and factors that are involved in chromosome segregation in the mammalian oocyte. Using RNA interference (RNAi) we have begun to explore the role of ATRX, (a
chromatin remodeling protein) during meiosis. ATRX becomes exclusively associated with the centromeres of meiotic chromosomes, where it is required to mediate chromosome stability. Loss of
ATRX function results in chromosome segregation defects leading to aneuploidy and severely reduced fertility. This lecture will discuss the role of ATRX and associated chromatin remodeling proteins in the
epigenetic control of centromere function in mammalian oocytes and embryos as well as potential
clinical implications to prevent the onset of aneuploidy in the human oocyte and pre-implantation embryo.
THE MINIMAL OOCYTE – OR HOW TO CONSTRUCT AN ARTIFICIAL EGG? WHAT ARE THE REQUIREMENTS FOR THE OOCYTE TO ACHIEVE IT
MISSION Gerald Schatten, USA
With dramatic advances is stem and somatic cells entering into gametogenesis lineages, the previously strict distinction between the mortal somatic lineage and
the potentially immortal germ line is now blurred. In this talk, the merits, challenges and possibilities of generating oocytes either in vitro or via xenografts
as well as the utilities of these biomanufactured gametes.
HUMAN TUBAL FLUID: IN VIVO AND IN VITRO
Patrick Quinn, USA
The physico and chemical environment in the human fallopian tube nourishes
and protects the oocyte and early preimplantation embryo from the time of ovulation, through fertilization to the early morula stage on day 3 after
ovulation. A major aspect of ART since it was first performed in both humans
and other mammals has been to create a culture fluid to support this early embryogenesis in vitro. In my talk I will discuss not only how the chemical
composition of media used for fertilization and the culture of early cleavage stage human embryos has been developed but also physical aspects of the
culture system including pH and temperature parameters. Emerging
technologies with respect to new media formats, embryo selection and refinements of culture systems will round-out the talk.
S-16
HOW ANDROGENS AND GENES AFFECT FOLLICLE MATURATION AND
OVARIAN AGING Norbert Gleicher, USA
For the longest, androgens have been considered detrimental to follicle maturation. Due to observations in rodents and humans, this view has,
however, in recent years undergone considerable change. From work in androgen receptor knock out mice (ARKO) mice, it has now
become abundantly clear that androgens, indeed, are essential for normal follicle growth. Since androgen receptors are present on granulosa cells only
at small growing follicle stages, beneficial androgen effects have to occur at
these early follicle development stages. These rodent data also offer explanation for the reported success of dehydroepiandrosterone (DHEA) supplementation in women
with diminished ovarian reserve (DOR), a treatment now widely utilized all over the world. Our research, therefore, suggests two potentially new directions in reproductive endocrinology and
infertility: By apparently successfully treating small growing follicles with androgens, weeks to month
before these follicles reach pre-ovulatory gonadotropin-sensitive stages, we, after over 50 years of concentration on only the gonadotropin-sensitive stage of folliculogenesis, point toward the possibility of
earlier intervention into follicle maturation. Our DHEA data, indeed, suggest that such earlier interventions may, for the first time, offer the opportunity of still being able to influence egg quality. Our
FMR1 data, in turn, suggest that such interventions can be selected based on a patient's genetic make up.
HOW DO OOCYTES TELL TIME? (OOCYTE AGING AND CAN THE
CHRONOLOGY SENSING MACHINERY BE RESET) Gerald Schatten, USA
The consequences of reproductive aging in women are far too often heart-
breaking and it is an enormous societal problem at which many sophisticated and emerging ART treatments are directed. Against background, the fundamental
mechanisms of aging at the cellular and molecular levels are being elucidated, so
biological solutions for these demographic challenges could be envisioned. At the heart of the question is: “how do oocytes know that they are to remain viable
within the ovaries of a 38 year old woman, and why do their reproductive potentials largely expire once the woman is 42 years old?”
S-17
FEMALE REPRODUCTIVE AGING: NEW INSIGHTS INTO AN OLD
PROBLEM Mary Herbert, UK
Female reproductive lifespan is curtailed by depletion of the germ cell pool and by a prevalence of meiotic segregation errors resulting in aneuploid
oocytes and a dramatically increased incidence of infertility, miscarriage, and birth defects. Despite its importance to human reproductive health,
the biological basis for the association between meiotic errors and the decline in the germ cell pool during female ageing has until recently
remained poorly understood. Recent findings from our lab (Lister et al,
2010, Curr. Biol., 20) and others (Chiang et al, 2010, Curr. Biol. 20) indicate that female ageing is accompanied by depletion of cohesin proteins, which mediate cohesion
between sister chromatids. Cohesion between sisters is essential for maintaining the bivalent chromosome structure required for accurate segregation of dyads during the first meiotic division (MI).
Consistent with this, two key features of bivalent structure – physical linkages at chiasmata and tightly
associated sister centromeres – were disrupted in oocytes from aged mice. This was associated with a dramatically increased incidence of anaphase defects during MI. Our findings give ground to the
hypothesis that gradual depletion of chromosomal cohesin in oocytes results in loss of the chromosome architecture required for accurate segregation during MI. Our current investigations are focused on
determining the clinical significance of cohesin depletion and deciphering how it is related to germ cell depletion during female aging.
THE IMPACT OF Y CHROMOSOME LIKE REGIONS OF THE X
CHROMOSOME (PALINDROMES AND AMPLICONS) ON OVARIAN RESERVE
Sherman Silber, USA
The Y chromosome contains 60 multicopy genes composed of nine different gene families concentrated in remarkable repeat regions of DNA sequence
called amplicons, arranged in mirror images called palindromes. This pattern is
very susceptible to deletions caused by homologous recombination with itself. In fact the most common types of mutation would not be those found in
conventional regions of sequence that harbor simple single gene polymorphisms but rather in these areas of repeat sequence and multicopy genes that have thus far only been well
described for the Y. For most of the human genome (which has been incorrectly thought to be fully
sequenced), these regions of amplicons and palindromes are like the “dark side of the moon.” Twelve percent of the X chromosome has this Y-type structure and is likely to harbor many genes that control
ovarian reserve. One could also speculate that a loss of genes responsible for de novo male dominant expression (such
as autism) are most likely to be on the X chromosome, have not yet been ascertained, and they could
very well be located in these ampliconic regions of the X chromosome that have heretofore been undeciphered.
The fertilization process of the oocyte, embryo development and implantation in relation to various clinical conditionsDorint Hotel Don Giovanni Prague • Prague, Czech Republic • November 8-11, 2012
23
The fertilization process of the oocyte and embryo development in relation to various clinical conditions
Dorint Hotel Don Giovanni PraGUe Prague, CzeCh rePubliC • November 8-11, 2012
POSTERS
www.comtecmed.com/OC/2012 • [email protected]
39-49-OC II- part 3.indd 1 22/10/12 12:06:07
The fertilization process of the oocyte, embryo development and implantation in relation to various clinical conditionsDorint Hotel Don Giovanni Prague • Prague, Czech Republic • November 8-11, 2012
P-1
LIST OF POSTERS
Friday, November 9, 2012
1 INSUFFICIENCY OF SPINDLE ASSEMBLY CHECKPOINT IN MOUSE OOCYTES M. Anger1,2, J. Sebestova1,2, A. Danylevska1,2
1CEITEC - Veterinary Research Institute, Brno, Czech Republic; 2Institute of Animal Physiology and Genetics, Libechov, Czech Republic
2 PCBS EXPOSURE CAUSES EPI/GENETIC DEFECTS OF SHEEP FOETAL FIBROBLASTS D.A. Anzalone, S. Sampino, M. Czernik, D. Iuso, P. Loi, G. Ptak University of Teramo, Teramo, Italy
3 EFFICIENCY OF FROZEN OOCYTES FOR POOR RESPONDER’S PATIENTS M. Badalotti1,2, V. Reig1, A. Tagliani-Ribeiro1, D. Kvitko1, L. Okada1, R. Azambuja1, F. Badalotti1, R. Petracco1, J. Michelon1,2, A. Petracco1,2
1Fertilitat Centro de Medicina Reprodutiva; 2Departamento de Ginecologia, Faculdade de Medicina, PUCRS Porto Alegre, RS, Brasil
4 MARKERS OF OOCYTE QUALITY FOR OOCYTE CRYOPRESERVATION M. Barberi1, G. Gioacchini2, O. Carnevali2, E. Giorgini2, V. Bianchi1, M.A. Bonu1, R. Canipari3, A. Borini1
1Centre for Reproductive Health, Bologna, Italy; 2Università Politecnica delle Marche, Ancona, Italy; 3‘La Sapienza’ University of Rome, Italy
5 ANALYSYS OF OVARIAN FOLLICULAR DEGENERATION CAUSED BY CHRONIC INGESTION OF ETHANOL IN WISTAR RATS I. Bezerra Lima-Verde1, J.C. Santos1, M. Dos Santos Silva1, F. De Santana2, G. Calado De Melo1, M.H. Tavares De Matos2, R.C. Cavalcanti De Albuquerque Jr1, J. Cordeiro Cardoso1
1University Tiradentes; 2Federal University of São Francisco Valley, Brazil
6 SUPPLEMENTED EFFECTS OF VASCULAR ENDOTHELIAL GROWTH FACTOR DURING IN VITRO MATURATION OF PORCINE CUMULUS OOCYTE COMPLEXES AND EMBRYOS PRODUCED BY SOMATIC CELL NUCLEAR TRANSFER D. Biswas1,2, S.H. Hyun1
1Chungbuk National University, Chungbuk, South Korea; 2Chittagong Veterinary and Animal Sciences University, Pahartali, Bangladesh
7 CYCLIC GUANOSINE MONOPHOSPHATE DOES NOT INHIBIT MITOGEN-ACTIVATED PROTEIN KINASE SIGNALING AND EXPRESSION OF CUMULUS EXPANSION-RELATED GENES IN PORCINE CUMULUS-OOCYTE COMPLEXES M. Blaha, R. Prochazka, L. Nemcova Academy of Sciences of the Czech Republic, Libechov, Czech Republic
Board # GROuP A
39-49-OC II- part 3.indd 2 22/10/12 12:06:08
The fertilization process of the oocyte, embryo development and implantation in relation to various clinical conditionsDorint Hotel Don Giovanni Prague • Prague, Czech Republic • November 8-11, 2012
P-2
LIST OF POSTERS
Friday, November 9, 2012
8 POLO-LIKE KINASE I CONTROLS NUCLEAR ENVELOPE BREAK DOWN AND CHROMOSOME DYNAMICS IN MEIOSIS I A. Brzáková1, P. Šolc1, T. Kitajima2, V. Baran3, V. Mayer1, P. Šámalová1, J. Motlík1, J. Ellenberg2
1AV CR, Libechov, CR; 2EMBL, Heidelberg, Germany; 3Institute of Animal Physiology, Kosice, Slovakia
9 GONADAL FOXO EXPRESSION IN THE GERMLINE AND SOMATIC COMPARTMENTS OF DIVERSE MAMMALIAN SPECIES D. H. Castrillon, E. Tarnawa, M. D. Baker, G. Aloisio UT Southwestern Medical Center, Dallas, TX, USA
10 COMPARISON OF PROLACTIN, FREE T3 AND FREE T4 LEVELS IN THE FOLLICULAR FLUID OF INFERTILE WOMEN AND HEALTHY FERTILE OOCYTE DONORS M. Cedikova1, V. Babuska1, N. Zech2, M. Kralickova1
1Charles University in Prague, Plzen, Czech Republic; 2Institute of Reproductive Medicine and Endocrinology, Plzen, Czech Republic
11 IMPROVED BLOOD SUPPLY BY SUBCUTANEOUS INJECTION OF HUMAN ENDOTHELIAL PROGENITOR CELLS (HEPCS) MAY INCREASE SURVIVAL OF TRANSFERRED VITRIFIED/ WARMED MOUSE OVARY S.K. Cha, M.K. Kim, D.H. Shin, J.M. Kim, W.S. Lee, T. K. Yoon, D.R. Lee CHA University College of Medicine, Seoul, Korea
12 DISTRIBUTION OF THE INSLQ VARIANT IN LUTEINIZING HORMONE RECEPTOR (LHCGR) IN FERTILE CZECH MALE AND FEMALE CONTROLS J. Chrudimská, P. Krenková, M. Macek jr., M. Macek sr. Department of Biology and Medical Genetics, Charles University Prague – 2nd Faculty of Medicine, University Hospital Motol, Prague, Czech Republic
13 ULTRASTRUCTURE ANALYSIS OF BLASTOCYSTS PRODUCED BY SOMATIC CELL NUCLEAR TRANSFER (SCNT) M. Czernik1, F. Zacchini1, F. Di Egidio1, D. Iuso1, J. Modlinski2, P. Loi1, G. Ptak1 1Department of Comparative Biomedical Science, University of Teramo, Teramo, Italy; 2Department of Experimental Embryology, Institute of Genetics and Animal Breeding of the Polish Academy of Science, Jastrzebiec, Poland
14 OVARIAN STIMULATION PRECEDING CANCER THERAPY DOES NOT EFFECT OVARIAN RESPONSE TO SUBSEQUENT GONADOTOXIC TREATMENT K.E. Dillon1, M.D. Sammel1, J.P. Ginsberg3, Y. Gosiengfiao4, M. Prewitt1, C.R. Gracia1
1University of Pennsylvania, Philadelphia, USA; 2Children's Hospital of Philadelphia, Philadelphia, USA; 3University of North Carolina, Chapel Hill, USA; 4Children's Memorial Hospital, Chicago, USA
Board # GROuP A
39-49-OC II- part 3.indd 3 22/10/12 12:06:09
The fertilization process of the oocyte, embryo development and implantation in relation to various clinical conditionsDorint Hotel Don Giovanni Prague • Prague, Czech Republic • November 8-11, 2012
P-3
LIST OF POSTERS
Friday, November 9, 2012
15 DYNAMICS OF DNA METHYLATION LEVELS IN RABBIT PREIMPLANTATION EMBRYOS DEVELOPED IN VIVO OR IN VITRO V. Duranthon1, A. Reis e Silva1, C. Bruno1, R. Fleurot1, N. Daniel1, P.G. Adenot1, C. Archilla1, N. Peynot1, C.M. Lucci2, N. Beaujean1
1INRA UMR 1198, Jouy en Josas. France; 2Faculty of Veterinary Medicine, Brasilia, Brasil
16 IN VITRO EMBRYO DEVELOPMENT AFFECTS MATURATION OF PLACENTAL VESSELS A. Fidanza, P. Toschi, C. Palmieri, P. Loi, G. Ptak Department of Biomedical Sciences, University of Teramo, Italy
17 PROTEOMIC BIOMARKERS OF PRETERM BIRTH RISK IN WOMEN WITH POLYCYSTIC OVARY SYNDROME (PCOS): A SYSTEMATIC REVIEW AND BIOMARKER DATABASE INTEGRATION N. Galazis1, N. Docheva2, K. Nicolaides1, W. Atiomo2
1North Central Thames Foundation School - UCL, UK; 2Nottingham University Medical School, UK
18 PROTEOMIC BIOMARKERS FOR OVARIAN CANCER RISK IN WOMEN WITH POLYCYSTIC OVARY SYNDROME (PCOS). A SYSTEMATIC REVIEW AND BIOMARKER DATABASE INTEGRATION N. Galazis1, S. Drymiotou2, S.N. Thoukididou2, W. Atiomo2
1North Central Thames Foundation School; 2Nottingham University Medical School, UK
19 A NEW APPROACH TO EVALUATE AGING EFFECTS ON HUMAN OOCYTES: FPA FTIR IMAGING ANALYSIS G. Gioacchini1,2, E. Giorgini2, V. Bianchi1, P. Ferraris3, C. Conti2, L. Vaccari3, O. Carnevali2, A. Borini1 1Tecnobios Procreazione, Centre for Reproductive Health, Bologna, Italy; 2Dipartimento di Scienze della Vita e dell’Ambiente, Università Politecnica delle Marche, Ancona, Italy; 3SISSI Beamline, Elettra Synchrotron Light Laboratory, Trieste, Italy
20 FERTILITY PRESERVATION COUNSELING PRIOR TO GONADOTOXIC TREATMENT A.R. Han, T.H. Lee, S.S. Jeon, Y.J. Cho Kyungpook National University Hospital, Daegu, Korea
21 THE TIMING OF EARLY EMBRYO CLEAVAGES–OBJECTIVELY MEASURABLE PREDICTOR OF HUMAN EMBRYO VIABILITY D. Hlinka1, S. Lazarovska1, M. Pichlerova1, I. Hamplova1, M. Stevikova1, J. Rutarova2, J. Razacova2, M. Dudas3
1Prague Fertility Centre, Prague, Czech Republic; 2Institute for the Care of Mother and Child, Prague, Czech Republic; 3P. J. Safarik University Institute of Biology and Ecology, Kosice, Slovakia
Board # GROuP A
39-49-OC II- part 3.indd 4 22/10/12 12:06:10
The fertilization process of the oocyte, embryo development and implantation in relation to various clinical conditionsDorint Hotel Don Giovanni Prague • Prague, Czech Republic • November 8-11, 2012
P-4
LIST OF POSTERS
Friday, November 9, 2012
22 TREATMENT OF SOMATIC CELLS WITH BIO IMPROVES THE NUCLEAR REPROGRAMMING OF SHEEP FIBROBLASTS D. Iuso University of Teramo, Teramo, Italy
23 IMPACT OF DHEA ON CLINICAL OUTCOME IN POOR RESPONDERS P.R. Jirge1,2, S.M. Chougule1, V. Sawant1, D.A. Bhomkar1
1Sushrut Assisted Conception Clinic, Kolhapur, India; 2Rajeev Gandhi University, Bangalore, India
24 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN(TCDD) INCREASES THE EXPRESSION OF CYCLOOXYGENASE-2 AND AROMATASE CYTOCHROME P 450 IN HUMAN ENDOMETRIUM Y.A. Kim, J.Y. Kim, K.C. Jun, D.Y. Chang, J.W. Park, Y.J. Choi, J.A. Jang Inje University Ilsan Paik Hospital, Goyangsi, S. Korea
25 COMPARISON OF HOMOCYSTEINE LEVELS IN THE FOLLICULAR FLUID OF INFERTILE WOMEN AND HEALTHY FERTILE OOCYTE DONORS M. Kralickova1, V. Babuska1, M. Cedikova1, B. Wirleitner2, N.H. Zech2
1Charles University in Prague, Plzen, Czech Republic; 2Institute of Reproductive Medicine and Endocrinology, Plzen, Czech Republic
26 GROUP IVA PHOSPHOLIPASE A2 COOPERATES WITH CYCLOOXYGENASE-2 TO OPTIMIZE OVULATION AND FERTILIZATION IN RODENTS S. Kurusu1, A Sapirstein2, J.V. Bonventre3
1Kitasato University School of Veterinary Medicine, Towada, Japan; 2Johns Hopkins University, Baltimore, USA; 3Brigham and Women's Hospital, Boston, USA
Board # GROuP A
39-49-OC II- part 3.indd 5 22/10/12 12:06:11
The fertilization process of the oocyte, embryo development and implantation in relation to various clinical conditionsDorint Hotel Don Giovanni Prague • Prague, Czech Republic • November 8-11, 2012
P-5
LIST OF POSTERS
Saturday, November 10, 2012
1 CONCENTRATIONS OF FOLLICULAR FLUID LEPTIN AND ADIPONECTIN CAN PREDICT QUALITY OF ENSUING OOCYTE AND EMBRYO J.H. Lee1, J.R. Lee1,2, H.J. Chang1, B.C. Jee1,2, C.S. Suh1,2, S.H. Kim2
1Seoul National University Bundang Hospital, Seongnam, Korea; 2Seoul National University College of Medicine, Seoul, Korea
2 CENTRALLY LOCATED GRANULAR CYTOPLASM OF THE OOCYTE: THE ULTRASTRUCTURAL ANALYSIS N. Makarova, L. Kazaryan, E. Kalinina, V. Polyakov, G. Baranova Research Center for Obstetrics, Gynecology and Perinatology named after V.I. Kulakov, Russia
3 BIOENERGY/OXIDATIVE STATUS OF EQUINE OOCYTES HELD IN THE ABSENCE OF MEIOSIS INHIBITORS BEFORE IN VITRO MATURATION N.A. Martino1, M.E. Dell'Aquila1, G.M. Lacalandra1, M. Filioli Uranio1, K. Hinrichs2
1University of Bari Aldo Moro, Italy; 2Texas A&M University, College Station, Texas, USA
4 PRESERVATION OF CAPRINE OVARIAN TISSUE USING DIFFERENT MEDIA AND INCUBATION PERIODS: EFFECTS ON MORPHOLOGY, APOPTOSIS AND DEVELOPMENT OF PREANTRAL FOLLICLES IN VITRO M.H.T. Matos1, R.J.S. Gonçalves1, A.Y.P. Cavalcante1, B.B. Gouveia1, T.L.B. Lins1, R.S. Barberino1, V.G. Menezes1, V.R.P. Barros1, L.P. Santos1, J.M.S. Santos1, J.R. Figueiredo2 1Federal University of San Francisco Valley, Petrolina, Brazil; 2State University of Ceara, Fortaleza-CE, Brazil
5 ANTI-MÜLLERIAN HORMONE DYNAMICS DURING CONTROLLED OVARIAN HYPERSTIMULATION L. Melado Vidales1, V. Fernandez Villafañez1, V. Verdú Merino1, J.M. Bajo Arenas1, I. Bruna Catalán2 1Clínica Ginefiv, Madrid; 2Hospital Universitario Montepríncipe, Madrid, Spain
6 AMH IS USEFUL TO PREDICT IVF/ICSI OUTCOME, OOCYTE MATURATION AND EMBRYO QUALITY L. Melado Vidales, V. Fernandez Villafañez, V. Verdú Merino, J.M. Bajo Arenas Clínica Ginefiv, Madrid
Board # GROuP B
39-49-OC II- part 3.indd 6 22/10/12 12:06:11
The fertilization process of the oocyte, embryo development and implantation in relation to various clinical conditionsDorint Hotel Don Giovanni Prague • Prague, Czech Republic • November 8-11, 2012
P-6
LIST OF POSTERS
Saturday, November 10, 2012
7 MOUSE ANTRAL NSN OOCYTE DEVELOPMENTAL ARREST IS ASSOCIATED WITH DEFICIENCY OF MATER AND CYTOPLASMIC LATTICES M. Monti1, M. Zanoni2, A. Calligaro3, M.S.H. Ko4, P. Mauri5, C.A. Redi1,2
1Fondazione IRCCS Ospedale San Matteo, Pavia, Italy; 2Laboratory of Developmental Biology, University of Pavia, Pavia, Italy; 3Department of Experimental Medicine, Histology and Embryology Unit, University of Pavia, Pavia, Italy; 4Laboratory of Genetics, National Institute on Aging, NIH, Baltimore, MD, USA; 5Proteomics and Metabolomics Unit, Institute for Biomedical Technologies (ITB-CNR), Segrate, Italy
8 LAPATINIB THROUGH EGFR TYROSINE KINASE INHIBITION AFFECTS OOCYTE MATURATION E. Nagyova1, L. Nemcova1, A. Mlynarcikova2, S. Scsukova2, J. Kalous1 1Institute of Animal Physiology and Genetics, Libechov, Czech Republic; 2Institute of Experimental Endocrinology, Bratislava, Slovakia
9 EFFECTIVENESS OF DIFFERENT MEIOTIC TRIGGERS UPON IN VITRO GROWN FOLLICLES APPEARS TO BE LINKED TO REGULATION OF THE CNP-NPR2 SYSTEM S. Romero, F. Sánchez, J. Smitz Vrije Universiteit Brussel, Brussels, Belgium
10 PATERNAL AGING INDUCE TRANSGENERATIONAL COMUNICATIVE DISFUNCTIONS IN MICE S. Sampino1, F. Zacchini1, J. A. Modlinski2, A.H. Swiergiel2, P. Loi1, G. Ptak1 1University of Teramo, Italy; 2Institute of Genetic and Animal Breeding, Italy
11 ALTERATION OF OVARIAN STEROIDOGENESIS BY THE ACTION OF POLYMERIC NANOPARTICLE POLY (ETHYLENE GLYCOL)-BLOCK-POLY (LACTIC ACID) (PEG-B-PLA) S. Scsukova1, A. Mlynarcikova1, K. Smolikova1, J. Jurcovicova1, E. Rollerova2 1Institute of Experimental Endocrinology Slovak Academy of Sciences, Bratislava, Slovak Republic; 2Department of Toxicology Slovak Medical University, Bratislava, Slovak Republic
12 GAMETE SPECIFIC RECOMBINANT PROTEINS BASED CONTRACEPTIVE VACCINE A. Shrestha1, N. Gupta1, D. Munshi1, V.A. Srinivasan2, S. Rajan2, R. Matur2, A.K. Panda1, S.K. Gupta1
1National Institute of Immunology, New Delhi, India; 2Indian Immunologicals Limited, Hyderabad, India
13 FOLLICLE SIZE AND TRANSFERABLE EMBRYOS IN WOMEN, FOLLICULAR MARKERS TO IDENTIFY THE BEST MEDIUM SIZE FOLLICLES M.A. Sirard1, A.L. Nivet1, I. Dufort1, M.C. Leveillé2 1Centre de recherche en biologie de la reproduction, Université Laval, Québec, QC, Canada; 2Centre de Fertilité d’Ottawa, Canada
Board # GROuP B
39-49-OC II- part 3.indd 7 22/10/12 12:06:12
The fertilization process of the oocyte, embryo development and implantation in relation to various clinical conditionsDorint Hotel Don Giovanni Prague • Prague, Czech Republic • November 8-11, 2012
P-7
LIST OF POSTERS
Saturday, November 10, 2012
14 ANTI-ENDOMETRIAL DEVELOPMENTAL ACTION OF A SYNTHETIC GLUCOCORTICOID: INVOLVEMENT OF DECIDUAL PARACRINE AND OVARIAN ENDOCRINE MECHANISMS F. Spencer1, M.L. Thompson1, L. Qi2
1Southern University, Biological Sciences & Health Research Center, Baton Rouge, Louisiana; 2University of Illinois, Biomedical and Therapeutic Sciences, Peoria, Illinois, USA
15 INTERACTIVE ROLES BETWEEN OVARIAN AND UTERINE MECHANISMS IN THE REGULATION OF ENDOMETRIAL DEVELOPMENT F. Spencer1, M.L. Thompson1, L. Qi2
1Southern University, Biological Sciences & Health Research Center, Baton Rouge, Louisiana; 2University of Illinois, Biomedical and Therapeutic Sciences, Peoria, Illinois, USA
16 EFFECT OF THE FORM AND TEMPORAL ADDITION OOCYTE-SECRETED FACTORS DURING IN VITRO MATURATION OF MOUSE OOCYTES ON SUBSEQUENT EMBRYO AND FETAL DEVELOPMENT J. Sudiman, L. Ritter, D. Feil, D. Mottershead, J. Thompson, R. Gilchrist Robinson Institute, Research Centre for Reproductive Health, University of Adelaide, Adelaide, Australia
17 HOW THE EMBRYO DEALS WITH OOCYTE LEGACY: EARLY INSPECTING OF MITOCHONDRIAL POOL L. Surlan1, I. Golic2, M. Vucetic2, K. Velickovic2, V. Stankovic1, J. Micic1,2, J. Stojnic1,2, I. Tulic1,2, V. Otasevic2, B. Korac2, A. Korac2 1Clinic for Obstetrics and Gynecology Clinical Centre of Serbia, Belgrade, Serbia; 2University of Belgrade, Belgrade, Serbia
18 CHANGES IN CUMULUS CELL METABOLISM & MOTILITY IMMEDIATELY FOLLOWING FERTILIZATION DURING BOVINE IVF J. Thompson, M. Sutton-McDowall The Robinson Institute, School of Pediatrics and Reproductive Health, The University of Adelaide
19 TWO DIFFERENT WAYS TO DIE: APOPTOSIS AND AUTOPHAGY IN SHEEP MONOPARENTAL PLACENTAE P. Toschi, A. Fidanza, M. Czernik, P. Loi, G. Ptak Department of comparative biomedical sciences, University of Teramo, Italy
Board # GROuP B
39-49-OC II- part 3.indd 8 22/10/12 12:06:13
The fertilization process of the oocyte, embryo development and implantation in relation to various clinical conditionsDorint Hotel Don Giovanni Prague • Prague, Czech Republic • November 8-11, 2012
P-8
LIST OF POSTERS
Saturday, November 10, 2012
20 SPERM-DERIVED HISTONES CONTRIBUTE TO PERICENTRIC HETEROCHROMATIN IN HUMAN PRE-IMPLANTATION EMBRYOS C. Van de Werken1, G.W. Van der Heijden1, C.J.H. Van Veen-Buurman1, J.S.E. Laven1, A.H.F.M. Peters2, E.B. Baart1
1University Medical Center, Rotterdam, The Netherlands; 2Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland
21 LONG AND REGULAR MENSTRUAL CYCLES IN OOCYTE DONORS LEAD TO HIGHER PREGNANCY RATES IN IVF/ICSI RECIPIENTS R. Vassena1, A. Obradors1, R. Vidal1, O. Coll1, V. Vernaeve1,2
1Clinica EUGIN, Barcelona, Spain; 2Fundaciò EUGIN, Barcelona, Spain
22 SLOWER PRE-EMBRYO DEVELOPMENT WITH INCREASING SERUM LEVELS OF YKL-40 IN WOMEN UNDERGOING IN VITRO FERTILIZATION M.L. Wissing1, M. Aziz2, S.O. Skouby2, T. Hoest1, A.L. Mikkelsen1
1Department of Obstetrics and Gynecology, Holbaek Hospital; 2University of Copenhagen, Herlev Hospital, Denmark
23 LATE LUTEAL PHASE START CONTROLLED OVARIAN HYPERSTIMULATION FOR EMERGENCY FERTILITY PRESERVATION H.R. Wi1, J.R. Lee1,2, H. Youm1, B.C. Jee1,2, C.S. Suh1,2, S.H. Kim2 1Seoul National University Bundang Hospital, Seongnam, Korea; 2Seoul National University College of Medicine, Seoul, Korea
24 EFFECTS OF Г-SECRETASE INHIBITOR ON MOUSE EMBRYO IMPLANTATION G.J. Wu1,2, P.W. Chu1,2, Y.P. Wang2, I.C. Chen2 1National Defense Medical Center; 2Tri-Service General Hospital, Taipei, Taiwan
25 EFFECTS OF Г-SECRETASE INHIBITOR ON EMBRYO IMPLANTATION AND EARLY PLACENTATION G.J. Wu1,2, P.W. Chu1,2, Y.P. Wang2, I.C. Chen2 1Graduate Institute of Medical Sciences, National Defense Medical Center; 2Department of Obstetrics and Gynecology, Tri-Service General Hospital, Taipei, Taiwan
26 EFFECT OF NECROSTATIN ON OVARIAN CRYOPRESERVATION AND TRANSPLANTATION H. Youm1, J.R. Lee1,2, H.J. Chang1,2, B.C. Jee1,2, C.S. Suh1,2, S.H. Kim2
1Seoul National University Bundang Hospital, Seongnam, Korea; 2Seoul National University College of Medicine, Seoul, Korea
Board # GROuP B
39-49-OC II- part 3.indd 9 22/10/12 12:06:14
The fertilization process of the oocyte, embryo development and implantation in relation to various clinical conditionsDorint Hotel Don Giovanni Prague • Prague, Czech Republic • November 8-11, 2012
48
OvaRIan CLub II PaRTICIPanTS CamE FROm...38 countries
Argentina Australia Austria Bangladesh
Belgium Brazil Bulgaria Canada
Chile China Czech Republic Denmark
Finland France Germany Hungary
India Ireland Israel Italy
Japan Korea Norway Poland
Romania Russia Serbia Slovak Republic
South Korea Spain Sweden Switzerland
Taiwan The Netherlands UK Ukraine
Uruguay USA
39-49-OC II- part 3.indd 10 22/10/12 12:06:26
The fertilization process of the oocyte, embryo development and implantation in relation to various clinical conditionsDorint Hotel Don Giovanni Prague • Prague, Czech Republic • November 8-11, 2012
23
The fertilization process of the oocyte and embryo development in relation to various clinical conditions
Dorint Hotel Don Giovanni PraGUe Prague, CzeCh rePubliC • November 8-11, 2012
InDEX
www.comtecmed.com/OC/2012 • [email protected]
39-49-OC II- part 3.indd 11 22/10/12 12:06:31
I
PPrrooggrraamm
PPaaggee AAbbssttrraacctt
PPaaggee PPrrooggrraamm
PPaaggee AAbbssttrraacctt
PPaaggee
AA CC ((ccoonn''tt))
Adenot, P.G. P-3 Cho, Y.J. P-3 Albertini, A. 14, 17 S-1, S-12 Choi, Y.J. P-4 Aloisio, G. P-2 Chougule, S.M. P-4 Anckaert, E. 17 Chrudimská, J. P-2 Anger, M. P-1 Chu, P.W. P-8 Anzalone, D.A. P-1 Coll, O. P-8 Arav, A. 14 S-3 Conti, C. P-3 Archilla, C. P-3 Cordeiro Cardoso, J. P-1 Atiomo, W. P-3 Crosignani, P. 15, 19 S-6 Azambuja, R. P-1 Czernik, M. P-1, P-2, P-7 Aziz, M. P-8 DD
BB Daniel, N. P-3 Baart, E.B. 16 S-8, P-8 Danylevska, A. P-1 Babuska, V. P-2, P-4 Dattilo, M. 15 Badalotti, F. P-1 De La Fuente, R. 18 S-15 Badalotti, M. P-1 De Santana, F. P-1 Bajo Arenas, J.M. P-5 De Ziegler, D. 16, 19 S-8 Baker, M. D. P-2 Dekel, N. 15 S-5 Baran, V. P-2 Dell'Aquila, M.E. P-5 Baranova, G. P-5 Di Egidio, F. P-2 Barberi, M. P-1 Dillon, K.E. P-2 Barberino, R.S. P-5 Docheva, N. P-3 Barros, V.R.P. P-5 Dos Santos Silva, M. P-1 Beaujean, N. P-3 Drymiotou, S. P-3 Bezerra Lima-Verde, I. P-1 Dudas, M. P-3 Bhomka, D.A. P-4 Dufort, I. P-6 Bianchi, V. P-1, P-3 Duranthon, V. P-3 Biswas, D. P-1 EE Blaha, M . P-1 Ellenberg, J. P-2 Bonu, M.A. P-1 FF Bonventre, J.V. P-4 Feil, D. P-7 Borini, A. P-1, P-3 Fernandez Villafañez, V. P-5 Bruna Catalán, I. P-5 Ferraris, P. P-3 Bruno, C. P-3 Fidanza, A. P-3, P-7 Brzáková, A. P-2 Figueiredo, J.R. P-5 CC Filioli Uranio, M. P-5 Calado De Melo, G. P-1 Fleming, T. 17 S-12 Calligaro, A. P-6 Fleurot, R. P-3 Canipari, R. P-1 Friedler, S. 16 Carnevali, O. P-1, P-3 GG Castrillon, D. H. P-2 Galazis, N. P-3 Cavalcante, A.Y.P. P-5 Gilchrist, R. P-7 Cavalcanti De Albuquerque Jr, R.C. P-1 Ginsberg, J.P. P-2 Cedikova, M. P-2, P-4 Gioacchini, G. P-1, P-3 Cha, S.K. P-2 Giorgini, E. P-1, P-3 Chang, D.Y. P-4 Gleicher, N. 18, 19 S-16 Chang, H.J. P-5, P-8 Golic, I. P-7 Chen, I.C. P-8 Gonçalves, R.J.S. P-5
II
PPrrooggrraamm
PPaaggee
AAbbssttrraacctt
PPaaggee
PPrrooggrraamm
PPaaggee
AAbbssttrraacctt
PPaaggee
GG ((ccoonn''tt)) LL Gosiengfiao, Y. P-2 Lacalandra, G.M. P-5 Gouveia, B.B. P-5 Lalioti, M. 16 S-8 Gracia, C.R. P-2 Laven, J.S.E. P-8 Gupta, N. P-6 Lazarovska, S. P-3 Gupta, S. 15 P-6 Lee, D.R. P-2 HH Lee, J.H. P-5 Hamamah, S. 16 S-7 Lee, J.R. P-5, P-8 Hamplova, I. P-3 Lee, T.H. P-3 Han, A. R. P-3 Lee, W.S. P-2 Hartshorne, G. 15 S-7 Leveillé, M.C. P-6 Herbert, M. 19 S-17 Lins, T.L.B. P-5
Herr, J.C. 17 S-11 Loi, P. P-1, P-2, P-3, P-6, P-7
Hinrichs, K. P-5 Lucci, C.M. P-3 Hlinka, D. P-3 MM Hoest, T. P-8 Macek jr., M. P-2 Hourvitz, A. 15 S-4 Macek sr, M. P-2 Hunt, P. 15 S-5 Makarova, N. P-5 Hyun, S.H. P-1 Martino, N.A. P-5
II Mashiach, S. 17 Iuso, D. P-1, P-2, P-4 Matos, M.H.T. P-5
JJ Matur, R. P-6 Jang, J.A. P-4 Mauri, P. P-6 Jee, B.C. P-5, P-8 Mayer, V. P-2 Jenkins, J. 18 Melado Vidales, L. P-5 Jeon, S.S. P-3 Menezes, V.G. P-5 Jirge, P.R. P-4 Meseguer, M. 16 S-9 Jun, K.C. P-4 Michelon, J. P-1 Jurcovicova, J. P-6 Micic, J. P-7
KK Mikkelsen, A.L. P-8 Kalinina, E. P-5 Mlynarcikova, A. P-6 Kalous, J. P-6 Modlinski, J. P-2, P-6 Kazaryan, L. P-5 Moley, K.H. 17 S-13 Kim, J.M. P-2 Monti, M. P-6 Kim, J.Y. P-4 Motlik, J. 15, 18 S-5, P-2 Kim, M.K. P-2 Mottershead, D. P-7 Kim, S.H. P-5, P-8 Munshi, D. P-6 Kim, Y.A. P-4 NN Kitajima, T. P-2 Nagyova, E. P-6 Ko, M.S.H. P-6 Nemcova, L. P-1, P-6 Korac, A. P-7 Nicolaides, K. P-3 Korac, B. P-7 Nivet, A.L. P-6 Korach, K. 14, 15 S-6 Noyes, N. 14, 17 S-3 Kralickova, M. P-2, P-4 OO N�hqnry «/#S1# P-2 Obradors, A. P-8 Kurusu, S. P-4 Okada, L. P-1 Kvitko, D. P-1 Otasevic, V. P-7 Ozil, J.P. 17 S-11
III
PPrrooggrraamm
PPaaggee AAbbssttrraacctt
PPaaggee PPrrooggrraamm
PPaaggee AAbbssttrraacctt
PPaaggee
PP SS (con't) Palmieri, C. P-3 Shrestha, A. P-6 Panda, A.K. P-6 Silber, S. 14, 19 S-3, S-17
Park, J.W. P-4 Simón, C. 14, 16, 17
Patrizio, P. 14 S-2 Sinclair, K. 17 S-14 Peters, A.H.F.M. P-8 Sirard, M.A. P-6 Petracco, A. P-1 Skouby, S.O. P-8 Petracco, R. P-1 Smitz, J. P-6 Peynot, N. P-3 Smolikova, K. P-6 Pichlerova, M. P-3 ý rof /#S1# P-2 Platon, J.V. 16 Spencer, F. P-7 Polyakov, V. P-5 Srinivasan, V.A. P-6 Prewitt, M. P-2 Stankovic, V. P-7 Prochazka, R. P-1 Stevikova, M. P-3
Ptak, G. P-1, P-2, P-3, P-6, P-7 Stojnic, J. P-7
QQ Sudiman, J. P-7 Qi, L. P-7 Suh, C.S. P-5, P-8 Quinn, P. 15, 18 S-15 Surlan, L. P-7
RR Sutton-McDowall, M. P-7 Rajan, S. P-6 Svoboda, P. 17 S-12 Razacova, J. P-3 Swiergiel, A.H. P-6 Redi, C.A. P-6 TT Reig, V. P-1 Tagliani-Ribeiro, A. P-1 Reis e Silva, A. P-3 Tarnawa, E. P-2 Ritter, L. P-7 Tavares De Mato, M.H. P-1 Rollerova, E. P-6 Telfer, E. 14, 15 S-1 Romero, S. P-6 Thompson, J. 15, 17 S-13, P-7 Rubio, C. 16 S-10 Thompson, M.L. P-7 Rutarova, J. P-3 Thoukididou, S.N. P-3
SS Tilly, J. 14 S-1 Sakkas, D. 16 S-10 Toschi, P. P-3, P-7 ý «p dory «/#S1# P-2 Tulic, I. P-7 Sammel, M.D. P-2 VV Sampino, S. P-1, P-6 Vaccari, L. P-3 Sánchez, F. P-6 Van Blerkom, J. 17, 18 S-14 Santos, J.C. P-1 Van de Werken, C. P-8 Santos, J.M.S. P-5 Van der Heijden, G.W. P-8
Santos, L.P. P-5 Van Veen-Buurman, C.J.H. P-8
Sapirstein, A. P-4 Vassena, R. P-8 Sawant, V. P-4 Velickovic, K. P-7
Schatten, G. 14, 18, 19 S-15, S-16 Verdú Merino, V. P-5
Scsukova, S. P-6 Vernaeve, V. P-8 Sebestova, J. P-1 Vidal, R. P-8 Seli, E. 16 S-9 Vucetic, M. P-7 Sen, A. 15 S-4 Shin, D.H. P-2 Shoham, Z. 14, 19
IV
PPrrooggrraamm
PPaaggee AAbbssttrraacctt
PPaaggee
WW Wang, Y.P. P-8 Wi, H.R. P-8 Wirleitner, B. P-4 Wissing, M.L. P-8 Woods, D. 14 S-2 Wu, G.J. 18 P-8
YY Yoon, T. K. P-2 Youm, H. P-8
ZZ Zacchini, F. P-2, P-6 Zanoni, M. P-6 Zech, N. P-2, P-4
The Inverse Pyramid: Regulating FollicleNumber and Oocyte Quality
PARIS, FRANCE • NOVEMBER 14-17, 2013
ORGANIZING COMMITTEE
P. Bouchard, FranceP. Devroey, BelguimJ. Eppig, USAB. Fauser, The NetherlandsR. Fleming, UK
N. Gleicher, USAS. Hamamah, FranceK. Korach, USA S. Mashiach, IsraelJ. Motlik, Czech RepublicF. Olivennes, France
G. Schatten, USAZ. Shoham, IsraelJ. Smitz, BelgiumE. Telfer, UKJ. Thompson, Australia
www.comtecmed.com/OC/2012 • [email protected]
ABSTRACT SUBMISSION DEADLINE:AUGUST 27, 2012
54-56-notes.indd 2 22/10/12 12:50:41
The fertilization process of the oocyte, embryo development and implantation in relation to various clinical conditionsDorint Hotel Don Giovanni Prague • Prague, Czech Republic • November 8-11, 2012
55
The Inverse Pyramid: Regulating FollicleNumber and Oocyte Quality
PARIS, FRANCE • NOVEMBER 14-17, 2013
ORGANIZING COMMITTEE
P. Bouchard, FranceP. Devroey, BelguimJ. Eppig, USAB. Fauser, The NetherlandsR. Fleming, UK
N. Gleicher, USAS. Hamamah, FranceK. Korach, USA S. Mashiach, IsraelJ. Motlik, Czech RepublicF. Olivennes, France
G. Schatten, USAZ. Shoham, IsraelJ. Smitz, BelgiumE. Telfer, UKJ. Thompson, Australia
www.comtecmed.com/OC/2012 • [email protected]
ABSTRACT SUBMISSION DEADLINE:AUGUST 27, 2012
NOTES
54-56-notes.indd 3 22/10/12 12:50:44
The fertilization process of the oocyte, embryo development and implantation in relation to various clinical conditionsDorint Hotel Don Giovanni Prague • Prague, Czech Republic • November 8-11, 2012
56
NOTES
54-56-notes.indd 4 22/10/12 12:50:45
Ovarian Club IIMeeting
Friday, November 9th 201213.45 –14.15 h
Prague, Czech RepublicNovember 8 –11, 2012
Company Presentation on„New Horizons: The voice ofthe industry“
Julian Platon, MD PhD
The fertilization process of the oocyte and embryo development in relation to various clinical conditions
Dupha_Anz_Ovarian_Club_RZ 11.10.2012 10:55 Uhr Seite 1
Shortened summary of MENOPUR 1200 IU and 600 IU characteristics
Name of the product: MENOPUR 1200 IU. Powder for solution
for injection + solvent. MENOPUR 600 IU. Powder for solution
for injection + solvent. Composition: Menopur 1200 IU: Highly
purified HMG equal to 1200 IU FSH and 1200 IU LH in one vial.
Menopur 600 IU: Highly purified HMG equal to 600 IU FSH
and 600 IU LH in one vial. Indications: Treatment for infertility
in women and men (in women with anovulation who fail to
respond to treatment with clomiphene citrate; controlled ovarian
hyperstimulation during assisted reproduction; in men with
hypo/ normogonadotrophic hypogonadism). For details see SPC.
Contraindications: Hormone-dependent cancers. Gynaecological
haemorrhage of unknown aetiology, premature menopause,
enlarged ovaries and cysts (polycystic ovarian syndrome), states
incompatible with pregnancy. Pregnancy and lactation. Excessive
sensitivity to any of the medicinal product ingredients. For
details see SPC. Posology: individual, i.m. or s.c. administration.
For details see SPC. Special warnings (and special precautions
for use). Ovarian response to treatment ought to be monitored
owing to threatened ovarian enlargement or development of
OHSS. Potentially increased risk of thromboembolic disease
developing in women at high risk. Pregnancy and lactation: see
section Contraindications. Undesirable effects: Headache and
abdominal pain, nausea, vomiting, enlargement of abdominal
cavity, pelvic pain, OHSS, thromboembolic disease, reactions
at the site of injection, hypersensitivity. Overdose: Threatened
development of ovarian hyperstimulation. Interaction: No
interaction studies have been undertaken. Special precautions
for storage: Store in refrigerator (2°C - 8°C), after preparation
the solution can be stored at up to 25°C for a maximum period
of 28 days. Marketing authorisation holder: Ferring Léc iva, Inc.
Jesenice u Prahy, Czech Republic. Marketing authorisation
number: Menopur 1200 IU: 56/961/10-C, Menopur 600 IU:
56/960/10-C. Date of revision of the text: 01/06/2011. Available
solely against medical prescription. No coverage from public
health insurance funds. Prior to prescription, please seek full
information on the medicinal product at the following address:
FERRING Pharmaceuticals CZ s.r.o, K Rybníku 475, 252 42
Jesenice u Prahy. Telephone: +420 241 041 111
Adverse events should be reported.
Reporting forms and information can be found at www.yellowcard.gov.uk.
Adverse events should also be reported to Ferring Pharmaceuticals Ltd.
OC II cover-RUN.indd 2 22/10/12 12:21:39
The fertilization process of the oocyte and embryo development in relation to various clinical conditions
Dorint Hotel Don Giovanni PraGUe Prague, CzeCh rePubliC • November 8-11, 2012
PROGRAM
www.comtecmed.com/OC/2012 • [email protected]
MENOPUR Multidose is now available,offering a more convenient treatment option
compared to MENOPUR 75 IU3
MENOPUR Multidose is now available,offering a more convenient treatment option
compared to MENOPUR 75 IU3
Ferring International Center SAChemin de la Vergognausaz 50CH 1162 St-PrexSwitzerlandwww.ferring.com
More live births with MENOPUR®
vs. rFSH following IVF1,2
A fact you can hold on to
More live births with MENOPUR®
vs. rFSH following IVF1,2
A fact you can hold on to
OC II cover-RUN.indd 1 22/10/12 12:21:19